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2.1 Background and aim of the work 
 
Atrial natriuretic peptide (ANP), which belongs to the family of natriuretic peptides is a 
peptide hormone mainly secreted by the heart in response to atrial stretch. It plays a 
fundamental role in electrolyte and volume homeostasis through potent biological effects 
including natriuresis, diuresis and vasorelaxation. Biological effects of ANP are mainly 
promoted through two major biochemically and functionally distinct classes of ANP 
receptors: natriuretic peptide receptor-A (NPR-A), which activates a particulate guanlyate 
cyclase and leads to rise of cyclic guanosin-3’,5’-monophosphate and NPRC, which acts as 
clearance receptor and modulates additionally adenylate cyclase activity. The functions of 
ANP, however, are not only restricted to homeostasis of the reno-cardiovascular system, but 
also seem to play an important role in the immune system. ANP and its receptors were 
shown to be expressed in various organs of the immune system such as thymus, spleen, 
lymph nodes and macrophages. Expression is regulated by a variety of immunmodulating 
factors and further investigations revealed various effects of ANP on immune cells like 
macrophages or thymocytes. Additionally, elevated levels of plasma ANP could be detected 
in inflammatory states like acute asthma exacerbations, acute respiratory distress syndrome 
(ARDS) and septic shock. In the last years many investigations have been made regarding 
possible bronchoprotective effects of ANP in those pathophysiological conditions. The lung 
has the highest tissue concentration of specific ANP binding sites and is also a site of 
synthesis and release of ANP. Interestingly, up-to-date most efforts were maid to elucidate 
pulmonary effects of ANP regarding regulation of vascular tone and improvement of 
pulmonary endothelial cell function, but hardly any data exist concerning potential anti-
inflammatory effects of ANP in airway inflammation. The lung can be divided into two distinct 
compartments, the vascular compartment, in which endothelial cells are mainly involved in 
inflammatory processes and the airway compartment, where epithelial cells have great 
importance in orchestrating the immune response. In previous studies, we demonstrated that 
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ANP inhibits TNF-α induced NF-κB activation and subsequent expression of adhesion 
molecules in human endothelial cells. Moreover, we were able to show, that ANP prevents 
NF-κB activation and TNF-α release in murine macrophages. The airway epithelium serves 
as first line of defence with respect to various external stimuli and mediates the extravasation 
of leukocytes in the alveolar space. So far, no investigations have been made concerning 
anti-inflammatory effects of ANP on alveolar epithelial cells. 
 
Aim of the work was to elucidate whether ANP possess anti-inflammatory properties in 
airway inflammation. Therefore, we aimed to clarify the following question: 
 
 Does ANP have effects on TNF-α induced signal transduction in alveolar  
epithelium? 
 
 Does ANP show anti-inflammatory actions in the lung in vivo in a model of LPS-
induced sepsis? 
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2.2 Atrial natriuretic peptide (ANP) 
 
2.2.1 Discovery of natriuretic peptide family 
 
The atrial natriuretic peptide was first described by de Bold et al in 1981 (de Bold et al., 
1981), who discovered the natriuretic and diuretic capability of an atrial extract injected in 
rats. The biological agent found responsible for this effect was a small cyclic peptide of 28 
amino acids named atrial natriuretic peptide. In the following years other members of the so 
called natriuretic peptide family were discovered. BNP was isolated from porcine brain first 
and therefore named brain natriuretic peptide (Sudoh et al., 1988). Along the lines of the first 
two peptides, the third discovered family member was named C-type natriuretic peptide 
(CNP) (Sudoh et al., 1990). In 1992, another natriuretic peptide, dendroaspis natriuretic 
peptide (DNP) was first isolated from the venom of the green mamba (Dendroaspis 
angusticeps) (Piao et al., 2004) and recently discovered also in humans (Richards et al., 
2002). In addition, Urodilatin, which has four additional amino acids in comparison to ANP, is 
a product of alternative processing of pro-ANP by renal cells (Forssmann et al., 1998). ANP 
and BNP are mainly expressed in cardiac tissue, ANP in the atrium and BNP in the ventricle, 
while CNP is mainly expressed in the central nervous system and in the endothelium 
(Pandey, 2005). 
 
2.2.2 Structure and synthesis of ANP 
 
ANP is a cyclic 28 amino acid peptide with a disulfide bridge between two cysteine residues 
at position 7 and 23 (illustrated in figure 1). This 17 amino acid loop is highly conserved and 
essential for biologic activity. All natriuretic peptides are synthesized as preprohormones. 
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Cleavage of 151 amino acid (aa) preproANP results in the 126 aa pro ANP, which is the 
predominant storage form (Suttner and Boldt, 2004). Corin, a transmembrane cardiac serine 
protease, cleaves ANP upon secretion to build the C-terminal active peptide (aa 99-126) 
(Yan et al., 2000). ANP is primarily expressed and stored in atrial granules, from which it is 
released in response to atrial wall stretch resulting from increased intravascular volume. This 
release into the circulation is mediated by exocytosis (Newman et al., 1991).  
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figure 1  Structure of ANP (human) 
 
2.2.3 Receptors and signal transduction 
 
Natriuretic peptides mediate their effects through three transmembran receptors named 
natriuretic peptide receptor-A (NPR-A), NPR-B and NPR-C (Kuhn, 2003; Misono, 2002; 
Tremblay et al., 2002). NPR-A and NPR-B have guanylate cyclase activity and lead to 
increasing cyclic-guanosin-5’-monophosphat (cGMP) levels while NPR-C may function as 
clearance receptor and causes declining cyclic adenosin-5’-monophosphat (cAMP) 
concentrations. ANP binds to and exert its effects preferentially through NPR-A and NPR-C 
Introduction 
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(see figure 2). Binding to NPR-A results in the production of cGMP, a classic intracellular 
second messenger for which three classes of binding proteins are known: cGMP dependent 
proteinkinases (PKGs), cGMP binding phosphodiesterases and cyclic nucleotide-gated ion 
channels (Potter et al., 2005).  
  
NPR-A NPR-B NPR-C
ANP
CNPBNP
BNP
ANP
CNP
cGMPGTP cGMPGTP
cGMP cGMP cAMP
Extracellular
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Cell membrane
Ligand binding
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domain
Dimerization domain
 
 
figure 2  Natriuretic peptide receptors 
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2.2.4 Effects of ANP on blood pressure 
 
ANP release provokes a remarkable decrease in blood pressure. A combined effect on 
microvascular permeability, vasorelaxation, natriuresis and diuresis mediates the 
hypotensive property of ANP (Potter et al., 2005).  
ANP contributes to the blood volume homeostasis by changes in fluid balance and 
endothelial permeability. In the kidney, ANP increases glomerular filtration rate, inhibits 
sodium and water reabsorption, and reduces renin secretion (Nishikimi et al., 2005b). ANP 
also has direct effects on the heart. Mice lacking ANP or NPR-A suffer from cardiac 
hypertrophy, which is the result of a prolonged systemic hypertension and the loss of local 
inhibitory effect of heart growth (Nishikimi et al., 2005a; Kuhn, 2005).  
 
2.2.5 Effect of ANP on the immune system 
 
Besides its cardiovascular effects the natriuretic peptide system possesses various 
ascendancies on both the innate and adaptive immune system (Vollmar, 2005). First 
evidence for an involvement of ANP in immune regulation was gained when natriuretic 
peptide receptors where found in immune organs such as thymus, tonsil, spleen and 
macrophages (Vollmar and Schulz, 1990). In addition, macrophages were found to 
synthesize and release ANP in response to several inflammatory stimuli (Vollmar and 
Schulz, 1994). In the innate immune system, ANP is able to facilitate the defence of 
macrophages in response to pathogens by improving their release of reactive oxygen 
species and by enhancing their phagocytosis activity (Mattana and Singhal, 1993).  For an 
appropriate immune response it is not only important to have an inflammatory response in 
the beginning, but also to resolve the inflammation. An overwhelming inflammatory response 
is as harmful as the infection itself, because of its ability to destroy tissues and to lead to a 
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generalized inflammatory response, called sepsis. ANP has shown anti-inflammatory 
properties in macrophages and endothelial cells. In macrophages it could be demonstrated, 
that ANP inhibits LPS induced iNOS activation and resultant NO production on 
transcriptional, posttranscriptional and substrate availability level. This is regulated via an 
autocrine mechanism (Kiemer and Vollmar, 1998). Via NPR-C and abased cAMP levels, 
ANP reduces both COX-2 mRNA and protein expression in macrophages exposed to LPS 
(Kiemer et al., 2002c). Cytokines play an essential role in the inflammatory process. ANP 
was found not only to reduce LPS-induced TNF-α secretion from macrophages via inhibition 
of NF-κB and AP-1 (Kiemer and Vollmar, 2001), it also demonstrated major impact on TNF-α 
effector functions in endothelial cells such as expression of adhesion molecules, expression 
of MCP-1 and increase of endothelial cell permeability (Kiemer et al., 2005). Additionally, 
ANP also seems to exert cytoprotective effects as seen in several models of 
ischemia/reperfusion injury (Gerwig et al., 2003). 
 
2.2.6 Effects of ANP on the lung 
 
ANP and it’s receptors are also strongly expressed in the pulmonary system (Gutkowska and 
Nemer, 1989). NP receptors have been found in endothelial and smooth muscle cells as well 
as in alveolar cells throughout the lung (Perreault and Gutkowska, 1995). Various biological 
effects are provoked by ANP in pulmonary functions as illustrated in figure 3. Alveolar type II 
cells as well as respiratory epithelial cells are capable of synthesizing ANP. In tracheal and 
bronchial smooth muscle cells a bronchorelaxation is induced, in pulmonary arteries and 
also in pulmonary veins an increase in cGMP levels and subsequent vasodilatation can be 
observed. On account of this, ANP is a prominent regulator of the pulmonary vascular tone 
(Perreault and Gutkowska, 1995). In addition, antiproliferative effects of ANP in human 
airway smooth muscle cells, mediated through both cGMP-dependent and cGMP-
independent mechanisms, has been reported (Hamad et al., 2003). ANP has also shown to 
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ameliorate the capillary function of pulmonary endothelial cells in hypoxia induced 
inflammation and therefore demonstrates direct cytoprotective effects on lung epithelium 
(Irwin et al., 2005). Bronchomotor responses in asthmatic patients are accompanied by an 
elevation of plasma ANP.  
Clearance of ANP
Bronchorelaxation
Vasorelaxation
Lung Permeability
Release of ANP
Surfactant Production
Anti-inflammatory ?
Cytoprotection
 
figure 3 Effects of ANP in the lung 
 
Exogenous ANP reverses bronchoconstriction when given intravenously or by inhalation 
(Hamad et al., 2003). First evidence of an anti-inflammatory property of ANP in the lung was 
given with the report, that ANP gene transfer attenuates airway reactivity in a mouse model 
of allergic sensitization (Kumar et al., 2002). In addition, ANP is elevated in patients suffering 
from septic shock and proANP can be utilised as a prognostic marker in sepsis 
(Morgenthaler et al., 2005).  
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2.3 Lung and inflammation 
2.3.1 Overview 
 
The lung possesses the largest combined epithelial and endothelial surface area of any 
organ in the body. Additionally, it has a large capillary bed and an extensive pool of 
neutrophils and is therefore exceedingly vulnerable during inflammatory processes like 
pneumonia and sepsis (Crimi and Slutsky, 2004). 
The lung can be divided into two major compartments, the vascular compartment, in which 
endothelial cells are mainly involved in the inflammatory response and the airway 
compartment where epithelial cells have great importance in orchestrating the immune 
response. Being the first tissue to encounter the external environment, the airway epithelium 
serves as first line of defence regarding to a variety of external stimuli (Martin et al., 1997). In 
several studies, airway epithelial cells have shown their ability to express and secrete 
various immune molecules and mediators, such as cytokines, chemokines and adhesion 
molecules (Neff et al., 2006). Additionally, there is increasing evidence that the alveolar 
epithelium has an important function in initiation and exacerbation of the immune response in 
the lung through interaction with alveolar macrophages and recruiting leukocytes into the 
alveolar space (Beck-Schimmer et al., 2004). The recruitment of neutrophils to sites of acute 
inflammation plays a crucial role during inflammatory response. In this process, the 
expression of adhesion molecules on epithelial cells can be regarded as major step in host 
response to inflammatory processes like bacterial infection by initiating extravasation of 
leukocytes (Beck-Schimmer et al., 2002). 
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2.3.2 Acute respiratory distress syndrome (ARDS) 
 
ARDS is defined as clinical complication and severe form of acute lung injury with the 
following hallmarks according to the definitions of the American-European Consensus 
Conference Committee (AECCC): alveolar epithelial inflammation, non-cardiogenic 
pulmonary oedema, surfactant depletion, and inactivation and loss of normal endothelial 
reactivity (Artigas et al., 1998). More than a million people worldwide are affected by ARDS 
each year with a mortality of 30-50 % of all patients. Inflammatory mediators play a key role 
in the pathogenesis of ARDS, in which two distinct categories of provoking events can be 
discerned. Directly lung associated events like aspiration or pneumonia can be the cause of 
ARDS as well as events causing lung injury in an indirect way, e.g. sepsis or shock (Bhatia 
and Moochhala, 2004).  
Acute Respiratory Distress Syndrome
Initial Disease
Cytokines, Chemokines, Adhesion Molecules, Lipid Mediators, ROS
Chemotaxis, Leucocyte Adhesion and Activation, Vasodilatation, Capillary Leak
Endothelial Cells
Epithelial cells Neutrophils Monocytes
 
figure 4 The pathogenesis of ARDS 
(adapted from Bathia et al., 2004) 
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The inflammatory response involves the activation of alveolar macrophages, the additional 
recruitment of blood leukocytes and the production of a variety of mediators like cytokines, 
ROS, arachidonic metabolites, complement factors and the initiation of the coagulation 
cascade (Crimi and Slutsky, 2004). As a consequence of this inflammatory burst epithelial 
and endothelial disruption occurs, which leads to alveolar oedema, decreased lung 
compliance, and hypoxemia in the end. The complex process of pathogenesis of ARDS is 
illustrated in figure 4. Up to now mechanical ventilation is still the most important therapeutic 
approach (Groeneveld, 2002). 
 
2.3.3 Sepsis 
 
Louis Pasteur showed for the first time in 1879/1880, that bacteria were present in blood 
from patients suffering of puerperal septicaemia. Later he came to the conclusion, that 
sepsis is a systemic response to fight off pathogens (Annane et al., 2005). 
Nowadays sepsis is defined as a systemic inflammatory response syndrome (SIRS), which 
is caused by an infection, consisting of two ore more of the following syndromes: increased 
or decreased temperature or leukocyte count, tachycardia and rapid breathing (Levy et al., 
2003). Normally the local inflammatory process is tightly regulated by the immune and 
neuroendocrine system. Sepsis develops when host response to an infection becomes 
amplified and subsequently dysregulated. In the onset of the disease systemic inflammation 
occurs converting the local infection to sepsis, severe sepsis or septic shock (Karima et al., 
1999). The yearly incident rate of sepsis in the United States is 50-95 cases per 100 000 and 
has been increasing each year. This severe disease is responsible for 2 % of hospital 
admissions and 10 % of admissions to intensive care units (Annane et al., 2005). The 
mortality lies at approximately 30 %, and can rise up to 50 % in the group of elderly persons 
or in cases of septic shock. Sepsis mortality is numerically equivalent to mortality from acute 
myocardial infarction. In half of all cases of SIRS a microbiological diagnosis is made and the 
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definition of sepsis is fulfilled (Cohen, 2002). The commonest sites of infection which can 
lead to a sepsis are the lungs, abdomen, urinary tract and primary infection of the blood 
stream. 60 % of these cases were caused by gram-negative bacteria, the remainder by 
gram-positive bacteria. The most important pathogens provoking a gram-positive sepsis are 
Staphylococcus aureus strains and Streptococcus pneumoniae, Escherichia coli and 
Pseudomonas aeruginosa are the commonest gram-negative bacilli isolated from patients 
with sepsis, severe sepsis or septic shock (Annane et al., 2005). Invading microorganisms 
are detected by pattern recognition receptors expressed on the surface and in the cytosol of 
immune cells. They are able to recognize common structures of many microbial pathogens 
called pathogen associated molecular patterns (PAMPs), including endotoxins (LPS, see 
2.5), peptidoglycan, lipoteichoic acid, lipopeptides, flagelline and viral RNA (Van Amersfoort 
et al., 2003). One major group of pattern recognition receptors is the Toll-like-receptor (TLR) 
family. TLR4 for instance is important for recognition of LPS and subsequent LPS-induced 
signal transduction, which is characterised by an excessive production of pro-inflammatory 
mediators such as TNF-α. These cytokines are now able to initiate secondary inflammatory 
cascades like production of reactive oxygen species (ROS), prostaglandins, other cytokines 
and the up regulation of adhesion molecules which leads to extravasation of leucocytes into 
tissue, further release of ROS and proteases and in the end causes tissue destruction 
(Karima et al., 1999). Additionally, these cytokines in combination with the occurring vascular 
injury are also able to interfere with coagulation pathways leading to microthrombosis and 
tissue hypoperfusion (Jagneaux et al., 2004; Esmon et al., 1999). Moreover, release of large 
amounts of nitric oxide (NO) causes vascular relaxation and impaired myocardial function 
causing an endotoxin derived state of shock (Kirkeboen and Strand, 1999). This combination 
of tissue hypoxia and tissue destruction can lead to multiple organ failure and succeeding 
death (see figure 5). 
 
Introduction 
20 
Fibrinolysis
multiple 
organ failure
Tissue destruction Tissue hypoxia
Vascular injury
Microthrombosis
Endotoxic shock
Leucocyte
adhesion
Leucocyte
migration
Release 
of proteases
and ROS
Coagulation
system
Anti-
coagulation
system
Hypoperfusion
Myocardial
function
Vascular
relaxation
proinflammatory
mediators
PAMPs
 
 
figure 5 The pathogenesis of multiple organ failure 
  PAMPs: pathogen associated molecular patterns 
 (adapted from Karima et al. 1999) 
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2.4 Tumour necrosis factor-α (TNF-α) 
2.4.1 Overview 
 
Tumour necrosis factor (TNF-α) is a potent cytokine produced by many cell types in 
response to inflammation, injury, infection and other environmental challenges. The 70kDa 
glycoprotein can trigger manifold organism and cellular responses, including leukocyte 
activation and migration, fever, acute phase response, cell proliferation, differentiation and 
apoptosis (Tracey and Cerami, 1993; Aggarwal et al., 1985). Most commonly, binding of 
TNF-α to its receptors lead to the activation of two prominent transcription factors, AP-1 and 
NF-κB, being responsible for gene induction important for inflammatory responses.  
 
2.4.2 Receptors and signalling 
 
TNF-α, being active as self-assembling, non-covalent bound trimer, exerts its effects through 
two different receptors called TNFR1 and TNFR2. Those receptors trimerize when TNF-α, 
which exists both as membrane integrated and as soluble form, is bound and several 
adaptor molecules are recruited (Chan et al., 2000). Soluble TNF-α predominantly activates 
TNFR1, which has cytoplasmatic death domains (DD). In contrast, membrane bound TNF-α 
prefers TNFR2 mediating its effects through TRAF-interacting motifs (TIMs) in the 
cytoplasmatic domain (Grell et al., 1995). After binding to TNFR1, the complex translocates 
to cholesterol and sphingolipid enriched membrane microdomains called lipid rafts, in which 
it associates with receptor-interacting protein (RIP), TNF-receptor associated factor 2 
(TRAF2) and TNFR1-associated death domain protein (TRADD) forming a signalling 
complex (see figure 6). 
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figure 6  TNFR1 signalling 
 
This complex induces the activation and transcription of inflammatory genes like cytokines 
and adhesion molecules via the transcription factors NF-κB and AP-1 (Legler et al., 2003; 
Aggarwal, 2003). TNFR1 also activates both, pro- and anti-apoptotic pathways. This balance 
is tightly regulated at numerous levels including regulation of receptor/ligand expression, 
soluble decoy receptor expression and antiapoptotic ligand induction (Krippner-Heidenreich 
et al., 2002). 
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2.5 Lipopolysaccharide (LPS) 
2.5.1 Overview 
 
In the end of the 19th century, in Robert Koch’s laboratory a heat-resistant toxin was 
identified in the lysates of Vibrio cholerae, which was able to cause toxic shock in animals. 
Because it was not secreted by bacteria, it was called endotoxin. Nowadays the toxic 
principle is identified as a lipopolysaccharide being a major component of the outer 
membrane of gram-negative bacteria. LPS consists of a bisphosphorylated glycolipid (lipid 
A) and a hydrophilic polysaccharide. The latter is composed of a core and an O-specific 
chain, which has great importance in LPS heterogeneity between different bacteria. 
 
2.5.2 Receptor and signalling 
 
Once released, LPS binds to LPS-binding protein (LBP) and is delivered to the cell surface 
receptor CD14, from where it is transferred to Toll like receptor 4 (TLR4). Toll like receptors 
are an ancient family of pattern recognition receptors, which play a crucial role in early host 
defence against invading pathogens. They activate multiple steps in the inflammatory 
process, which are important to fight off the invading pathogens and to coordinate systemic 
defences. Up to present 10-15 different TLRs are known in diverse mammals, which can 
recognize various pathogen-associated molecular patterns (PAMPs) (Akira and Takeda, 
2004). LPS forms a receptor complex consisting of MD-2, an adaptor protein and dimerized 
TLR4. This stimulation of TLR4 triggers the association of myeloid differentiation  
primary-response protein 88 (MyD88) and other adaptor proteins like TRIF, TRAM and Mal. 
This in turn leads to recruiting of Interleukin-1R-associated kinase-4 (IRAK-4). This event 
allows the association and phosphorylation of IRAK-1 by IRAK-4.  Tumour-necrosis-factor-
recetor-associated-factor-6 (TRAF6) binds to IRAK-1 and once phosphorylated the IRAK-
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4/TRAF6 complex translocates into the cytoplasm. There transforming-growth-factor-β-
activated kinase (TAK1), TAK1-binding protein 1 (TAB1) and TAB2 are bound. TAK1 gets 
activated and in turn phosphorylates and activates both mitogen-activated kinase kinases 
(MAPKK) like MKK3/6 or MKK4/7 and the inhibitor of nuclear factor-κB (IκB)-kinase complex 
(IKK complex), consisting of IKK1, IKK2 and nuclear factor-κB (NF-κB) essential modulator 
(NEMO) (Karin and Delhase, 2000). The IKK complex phosphorylates IκBα, which leads to 
its ubiquitylation and subsequent degradation. This allows NF-κB to translocate to the 
nucleus and the expression of target genes is induced (Ravid and Hochstrasser, 2004) as 
illustrated in figure 7. 
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figure 7  LPS signalling 
 
Introduction 
25 
2.6 p38 mitogen activated protein kinase (p38 MAPK) 
 
The p38 MAPK is a member of the mitogen activated protein kinase family and its signalling 
transduction pathway has major impact in regulating various cellular responses including 
inflammation, cell differentiation, cell growth and death.  MAPK are members of discrete 
signalling cascades which consist of three protein kinases, a MAPK and two upstream 
components, MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK). Up to now, four 
isoforms of p38 have been described in mammalian cells (p38α, p38β, p38γ and p38δ). Of 
these homologues p38α is the most physiologically relevant kinase involved in inflammatory 
processes. p38 was originally identified in LPS-stimulated murine macrophages (Han et al., 
1994). For activation, p38 requires dual phosphorylation on Thr180 and Tyr182 by MKK3 
and MKK6. These MAPKK are activated by several MAPKKK depending on the decisive 
stimulus (Kyriakis and Avruch, 2001; Obata et al., 2000). Recent studies revealed an 
additional mechanism of p38 activation, which is independent of upstream MAPKK and 
involves TAB1 (transforming growth factor-β-activated protein kinase 1 (TAK1)-binding 
protein 1) (Ge et al., 2002). In response to LPS, p38 phosphorylates and activates a variety 
of transcription factors, that include ATF-2 (Chen et al., 1998) and Elk-1 (Raingeaud et al., 
1996). p38 kinase is essential for cytokine production following LPS treatment (Carter et al., 
1999b) and inhibition of p38 has shown to attenuate the severity of pancreatitis-induced 
adult respiratory distress syndrome (Denham et al., 2000). Additionally, p38 regulates TNF-α 
mRNA stability and reduces TNF-α transcription by  influencing transactivation of NF-κB 
(Campbell et al., 2004). Therefore, one aim of the present study was to elucidate potential 
effects of ANP on p38 MAPK in the mouse lung during LPS-induced sepsis. 
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2.7 Proteine kinase B / Akt  
 
Protein kinase B (PKB), also known and in the following termed as Akt, is a serine/threonin 
kinase which plays a critical role in the modulation of cell development, growth and survival. 
Akt is an important downstream target of phosphatidylinositol 3-kinase (PI3K). Synthesis of 
3’-phosphorylated inositides by PI3K after activation translocates Akt to the plasma 
membrane, where it is activated by a phosphoinositide-dependent kinase (PDK1) (Cantley, 
2002). Akt is the homologue of the transforming oncogene of the AKT8 oncovirus (ν-Akt). 
Three mammalian members of this family have been isolated so far termed Akt 1/2/3. They 
share >80 % amino acid homology and contain a conserved domain structure: a pleckstrin 
homology (PH) domain which mediated binding of Akt to 3’-phosphoinositides, a catalytic 
kinase domain containing a phosphorylation site at Thr308 and a regulatory C-terminal 
domain with a second regulatory phosphorylation site at Ser473. Phosphorylation of Thr308 
and Ser473 is essential for maximal Akt activation (Vivanco and Sawyers, 2002). 
Constitutive Akt signalling promotes proliferation and increased cell survival for example by 
phosphorylating and thereby inhibiting the pro-apoptotic protein BAD and by transcriptional 
regulation of pro and anti-apoptotic genes (Song et al., 2005). Recent reports revealed a 
growing evidence for participation of the PI3K/Akt pathway in LPS-induced inflammatory 
mechanisms (Guha and Mackman, 2002; Williams et al., 2004). Therefore, it seemed 
plausible to investigate whether Akt is involved in the effect of ANP on LPS-induced septic 
shock. 
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2.8 Adhesion Molecules 
2.8.1 Overview 
 
Two main pathways are responsible for regulating cell to cell communications: soluble 
factors like growth factors and cytokines, and a group of cell adhesion molecules (CAMs).  
These adhesion molecules can be subdivided into four groups: selectins, integrins, 
cadherins and immunoglobulin-like adhesion molecules. The latter is a family of more than 
70 known members of cell surface glycoproteins being characterised by immunoglobulin 
homology units, which consist of two anti-parallel beta sheets connected through two 
cysteine residues. As an example, T-cell receptor, Immunoglobulins, MHC-antigens, CD4, 
CD8 and ICAM-1 are members of this family (Aplin et al., 1998). 
 
2.8.2 ICAM-1 
 
ICAM-1 is a 505 aa transmembrane glycoprotein that consists of five immunoglobulin-like 
domains, a transmembrane segment and a cytoplasmatic tail. It is constitutively expressed 
on cell surfaces of a variety of cell types, e.g. fibroblasts, leucocytes, endothelial and 
epithelial cells in a low manner. The adhesive interactions are mediated by binding to two 
integrins belonging to the β2 subfamily, e.g. LFA-1 and Mac-1. ICAM-1 expression is 
predominantly transcriptional regulated. Up regulation occurs in response to a number of 
inflammatory mediators such as oxidative stress, virus infections or pro-inflammatory 
cytokines, and is associated with a variety of inflammatory diseases including asthma, 
atherosclerosis, ischemia reperfusion injury and ARDS (van de and van der Saag, 1996). 
The ICAM-1 promoter contains a large number of binding sites for inducible transcription 
factors, the most important of which is NFκ-B (Roebuck and Finnegan, 1999).  
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2.8.3 Role of ICAM-1 in lung inflammation 
 
The recruitment of leucocytes is one of the fundamental mechanisms involved in 
inflammatory processes. The migration of monocytes into the alveolar compartment can be 
regarded as crucial step in the development of acute and chronic lung injury (Mulligan et al., 
1993). This process requires the leucocytes to adhere and migrate through the vascular 
endothelium, through the extracellular matrix of endothelial and epithelial cells and in the end 
to cross the alveolar epithelial barrier. ICAM-1 has been shown to play a major role in 
recruiting leucocytes to sites of inflammation by mediating adherence of neutrophils to 
endothelial cells leading to subsequent extravasation (Bevilacqua et al., 1994). This 
adhesion is mediated through ICAM-1 in endothelial cells, and through CD11a/CD18 and 
CD11b/CD18 as receptors on neutrophils. Further, ICAM-1 is also expressed on alveolar 
epithelial cells on a low level and markedly upregulated in response to pro-inflammatory 
stimuli like TNF-α, LPS or IFN-γ (Beck-Schimmer et al., 2002; Paine, III et al., 1994). Recent 
studies revealed that ICAM-1 is also critically involved in target cell-effector cell interactions 
(Beck-Schimmer et al., 2004). These investigations indicate that ICAM-1 seems to be 
important for the adhesion of neutrophils and macrophages to stimulated alveolar epithelial 
cells and their subsequent cytotoxic actions. In addition, there is increasing evidence for the 
importance of soluble ICAM-1 in orchestrating the immune response in the airway 
compartment. Soluble ICAM-1 has been demonstrated to enhance alveolar macrophage 
production of macrophage inflammatory protein-1 and TNF-α. 
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3 Materials and methods 
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3.1  Cell culture 
 
3.1.1 Materials 
 
ANP (1-28, human) was purchased from Tocris (Westwood, Ellisville, USA), tumour necrosis 
factor-α (TNF-α) from tebu-bio (Offenbach, Germany). The protease inhibitor cocktail 
Complete was from Roche (Mannheim, Germany). All other materials except antibodies 
were purchased from either Sigma (Deisenhofen, Germany), Carl-Roth GmbH (Karlsruhe, 
Germany) or VWR International (Munich, Germany). ANP and TNF-α were diluted in 
phosphate buffered saline (PBS) containing 0.1 % bovine serum albumine (BSA). If not 
stated otherwise, all solutions were prepared with double-distilled water. 
 
3.1.2 Solutions 
 
Phosphate buffered saline (PBS) pH7.4  Trypsin/EDTA (T/E) 
Na2HPO4 10.4 mM  Trypsin   0.05 g 
KH2PO4 3.16 mM  (1:250 in PBS) 
NaCl 132.2 mM  Na2EDTA  0.20 g 
    PBS    ad 100.0 ml 
3.1.3 Type II alveolar epithelial cell line A549 
 
The human type II alveolar epithelial cell carcinoma A549 was graciously provided by  
Prof. Dr. E. Wagner (Department of Pharmacy, LMU Munich, Germany). This cell line 
provides most of the characteristics of type II alveolar epithelial cells (Nardone and Andrews, 
1979; Smith, 1977) 
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3.1.4 Culture of A549 
 
A549 were cultured in HAMs F12K medium (PAN Biotech, Aidenbach, Germany) 
supplemented with 10 % heat inactivated fetal calf serum (Biochrom, Berlin, Germany), 100 
U/ml penicillin and 100 µg/ml streptomycin in an incubator (Heraeus, Hanau, Germany) in a 
humidified atmosphere at 5 CO2 and 37°C. Cells were routinely tested for mycoplasma with 
the PCR detection kit VenorGeM (Minerva Biolabs, Berlin, Germany). 
 
3.1.5 Passaging 
 
For passaging of A549 cells, the medium was removed and the cells were washed three 
times with PBS.  Afterwards A549 where incubated with 2.5 ml T/E solution per 75 cm2 flask 
for 2 min at 37°C. The cells where gradually detached and the digestion of trypsin was 
stopped with HAMs F12K containing 10 % heat-inactivated FCS. After centrifugation at 150 x 
g, 4°C for 8 min the supernatant was discarded and the pellet was resuspended in HAMs 
F12K supplemented with 10 % heat-inactivated FCS and penicillin (100 U/ml)/streptomycine 
(100 ng/ml). A549 were subcultured 1:10 in culture flasks or plates and grown until 
confluence. 
 
3.1.6 Freezing and thawing 
 
For long-time storage cells were grown to confluence in 150 cm² flasks, trypsinized, 
centrifuged and resuspended in ice-cold freezing medium, containing 10% DMSO as 
cryoprotectant. 
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Freezing medium A549 
HAMs F12K 55 % 
FCS 40 % 
DMSO 10 % 
 
The resuspended cells were directly transferred to cryo-vials and frozen at -20°C for one 
day. Because successive freezing is required for survival of the cells, the vials were kept at -
80°C for another three days until long term storage in liquid nitrogen at -196°C. 
For thawing, the content of a cryo-vial was defrosted rapidly by dissolving in 20 ml of 
prewarmed cell culture medium, centrifuged and resuspended in culture medium. 
The culture was left to grow for at least 5 days before any experiments. 
 
3.2 LPS model of murine sepsis 
 
The following animal experiments were kindly performed by Dr. Martin Lehner (Biochemical 
Pharmacology, University of Konstanz) (see 3.2.3.1) and Ulla Gebert (Biochemical 
Pharmacology, University of Konstanz) as well as Melanie Keller (3.2.3.2). 
 
3.2.1 Animals 
 
Male BALB/c mice (pathogen-free, 22 ± 6 g) were provided by the in house Animal Breeding 
Facility of the University of Konstanz and housed in a temperature- and humidity-controlled 
room at 22°C and 55 % humidity under a constant 12 h light/dark cycle. Animals had free 
access to water and chow (Ssniff, Soest, Germany), but were fasted with free access to 
water 12 h prior to the in vivo experiment. All studies were performed with the permission of 
the government authorities, in accordance with the German Legislation on Laboratory Animal 
Experiments and followed the directives of the University of Konstanz Ethical Committee. 
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3.2.2 Materials and solutions 
 
ANP (1-28, rat) was purchased from Bachem (Heidelberg, Germany), Lipopolysaccharide 
(LPS) from Salmonella abortus equi S. from BIOCLOT (Aidenbach, Germany). Pentobarbital 
(Nembutal), which was used for anaesthesia of animals, was from Sanofi-Ceva (Hannover, 
Germany). All other materials were purchased from either Sigma (Deisenhofen, Germany) or 
VWR International™ (Munich, Germany). ANP and LPS were diluted in a total volume of 300 
µl sterile 0.9 % saline solution containing 0.1 % human serum albumin (HSA). 
 
3.2.3 Experimental setting and tissue sample generation 
3.2.3.1 TNF-α measurement in plasma and tissue samples 
 
In this experiment, mice received preconditioning with ANP prior to LPS challenge, in order 
to investigate potential effects of ANP pretreatment on the subsequent LPS-induced TNF-α 
expression. At the beginning of the in vivo experiment, either NaCl (0.9 %) or ANP (50 µg/kg 
b.w., 5 µg/kg b.w. or 0.5 mg/kg b.w.) was administered to mice intravenously. After a 
preconditoning period of 15 min, LPS (300 µg/kg b.w.) or NaCl (0.9%) were injected i.p.  
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figure 8 Experimental setting for TNF-α measurement in plasma and tissue 
samples (organ withdrawal) in a model of ANP preconditioning in LPS-
induced sepsis. Animals were injected i.v. with either NaCl (Co) or ANP (50 
µg/kg b.w., 5 µg/kg b.w. or 0.5 µg/kg b.w.) prior to i.p. LPS administration (300 
µg/kg b.w.). After 120 min and lethal anaesthesia blood was obtained and lungs 
were excised and snap frozen in liquid nitrogen for TNF-α measurement. 
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120 min afterwards blood and tissue samples were withdrawn after cardiac puncture and 
lethal i.v. anaesthesia and of mice with 150 mg/kg b.w. pentobarbital plus 0.8 mg/kg b.w. 
heparin and further handled as described in 3.10. Four treatment groups were generated, 
each group consisting of n = 4 animals. 
 
3.2.3.2 Experimental setting for tissue sample generation  
 
Mice were injected with either intravenous NaCl (0.9 %) or ANP (5 µg/kg b.w.). After a 
pretreatment period of 15 min animals received an i.p. injection of NaCl (0.9 %) or LPS  
(1 mg/kg b.w.). At the indicated times, blood and tissue samples were obtained after lethal 
intravenous anaesthesia of mice with 150 mg/kg b.w. pentobarbital plus 0.8 mg/kg b.w. 
heparin and snap-frozen in liquid nitrogen (figure 9). Four treatment groups were generated, 
each group consisting of n = 5 animals. 
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figure 9: Experimental setting for ANP preconditioning in vivo before LPS-induced 
septic shock ( organ withdrawal). 
 Animals were injected intravenously with either NaCl (Co) or ANP (5 µg/kg b.w.) 
15 min prior to i.p. LPS challenge (1mg/kg b.w.). or NaCl (0.9 %) injection. Co: 
NaCl treated i.v.; ANP: ANP i.v. after 15 min NaCl i.v.; LPS: NaCl i.v., after 15 
min LPS i.p.; ANP + LPS: ANP i.v., 15 min later LPS i.p. After lethal 
anaesthesia lungs were excised 15 min, 30 min or 90 min after LPS injection 
and snap-frozen in liquid nitrogen. 
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3.3 Western Blot analysis of protein 
3.3.1 Sample preparation 
 
3.3.1.1 Solutions 
 
Modified RIPA buffer (lysis buffer)   Lysis buffer for lung tissue 
NaCl 150 mM   NaCl   137 mM 
Tris-HCl 50 mM   Tris   20 mM 
Nonidet P-40 1.0 %   Na2EDTA   2 mM 
Sodium deoxycholat 0.25 %   Glycerol  10 % 
SDS 0.1 %   Na4P2O7  2 mM 
     Na2C3H7O6P  20 mM 
 
Added freshly before use: 
For inhibition of proteases 
Complete® 4 %   Complete®  4 % 
PMSF 1 mM   PMSF   1 mM 
For inhibition of phosphatases 
NaF 1 mM   NaF   10 mM 
Activated Na3VO4 1 mM   Activated Na3VO4 2 mM 
 
Laemmli sample buffer (3x) 
Tris-HCl 187.5 mM 
SDS 6.0 % 
Glycerol 30 % 
Bromphenolblue 0.015 % 
Added freshly before use: 
β-Mercaptoethanol 5 % 
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3.3.1.2 Preparation of whole cell lysates 
 
Cells were cultured in 6-well plates until 90 % confluence and were treated as indicated in 
the associated figure legend.  Subsequently, cells were washed with ice-cold PBS, lysed in 
modified RIPA buffer, homogenized and centrifuged (14,000 rpm, 4°C, 10 min). The 
supernatants were handled further on as described in 3.3.1.3. 
 
3.3.1.3 Preparation of whole organ lysates 
 
Approximately 20 mg of lung tissue were hackled and homogenized with a dounce 
homogenizer in 300 µl of lysis buffer in order to get a homogenous suspension. Afterward 
the samples were centrifuged (14,000 rpm, 4°C, 10 min), 10 µl of the supernatants were 
further diluted and used for determination of protein content and the remaining supernatant 
was diluted with Laemmli sample buffer (3x) and boiled at 95°C for 5 min. Samples were 
stored at -20°C until Western Blot analysis. 
 
3.3.1.4 Protein determination 
 
Protein concentrations were determined in order to ensure equal amounts of protein in all 
samples analyzed by Western Blot. Quantification was performed using the bicinchoninacid 
assay (BC assay reagents, Interdim, Montulocon, France) as described by Smith and  
co-workers (Smith et al., 1985). 
The blue complex was measured photometrically at 550 nm (TECAN Sunrise Absorbance 
reader, TECAN, Crailsheim, Germany). Protein standards were obtained by diluting a stock 
solution of Bovine Serum Albumin (BSA). Linear regression was used to determine the 
actual protein concentration of the samples. 
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3.3.2 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis  
3.3.2.1 Solutions 
 
Separation gel (10 %)  Stacking Gel 
PAA solution (30 %) 40 %   PAA solution (30 %) 17 % 
Tris-base pH 8.8 375 mM  Tris-HCl pH 6.8  125 mM 
SDS 0.1 %   SDS    0.1 % 
TEMED 0.1 %   TEMED   0.2 % 
APS 0.5 %   APS    1 % 
 
Electrophoresis buffer (1x)     
Tris 4.9 mM   
Glycine 38 mM   
SDS 0.1 %  
 
3.3.2.2 Electrophoresis 
 
The prepared lung and cell lysates described above were separated by denaturating sodium 
dodecylsulfat polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli 
method. SDS, a highly negative charged detergent binds to the hydrophobic parts of proteins 
and solubilizes them. After denaturating the proteins by reducing the disulfide binds with β-
mercaptoethanol and boiling the samples at 95°C for 5 min, the complexes of SDS with the 
denatured proteins have a large net negative charge that is roughly proportional to the mass 
of the protein. Their migration velocity during the electrophoretic separation is now roughly 
proportional to the mass of the protein. Equal amounts of protein were subjected to SDS-
PAGE (Mini-Protean 3, Bio-Rad, Munich, Germany) on a discontinuous polyacrylamide gel, 
consisting of separation gel (10 %) and stacking gel. Electrophoresis was carried out at  
100 V for 21 min for stacking and 200 V for 36 min for separation of the protein mixture.  The 
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molecular weight of the investigated proteins was determined by comparison with prestained 
protein standards (Caleidoscope protein marker, Bio-Rad, Munich, Germany). 
 
3.3.3 Western Blot 
3.3.3.1 Solutions 
 
Tris-buffered saline pH 8.0 containing 0.1 % Tween (TBS-T) 
Tris  24.6 mM 
NaCl  188 mM 
Tween 20  0.2 % 
 
Anode buffer    Cathode buffer 
Tris  12 mM  Tris    12 mM 
CAPS 8 mM  CAPS    8mM  
Methanol 15 %   SDS    0.01 % 
 
Coomassie staining solution   Coomassie destaining solution 
Coomassie brilliant blue G-250 3 %  Acetic acid (100 %)  10 % 
Acetic acid (100 %)  10 %  Ethanol (96 %)   33 % 
Ethanol (96 %)  45 %    
 
ECL solutions 
Solution A    Solution B 
Luminol  25 mM  H2O2 (30 %)    0.006 % 
p-Coumaric acid  0.396 mM Tris pH 8.5   100 mM 
Tris pH 8.5  100 mM  
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3.3.3.2 Antibodies 
 
Primary antibodies Diluted in Dilution manufacturer 
Rabbit anti IκBα 1 % Blotto in TBS-T 1: 1,000 Santa Cruz, Heidelberg, Germany 
Rabbit anti phospho-
IκBα(Ser 32) 5 % BSA in TBS-T 1:1,000 
Cell signalling, 
Frankfurt/Main, 
Germany 
Rabbit anti Akt  1 % Blotto in TBS-T 1:1,000 
Cell signalling, 
Frankfurt/Main, 
Germany 
Rabbit anti phospho 
Akt (Ser 473) 5 % BSA in TBS-T 1:2,000 
Cell signalling, 
Frankfurt/Main, 
Germany 
Rabbit anti p38 MAPK 5 % BSA in TBS-T 1:1,000 
Cell signalling, 
Frankfurt/Main, 
Germany 
Rabbit anti phospho 
p38 MAPK 
(Thr180/Tyr182) 
5 % BSA in TBS-T 1:1,000 
Cell signalling, 
Frankfurt/Main, 
Germany 
Secondary 
antibodies Diluted in Dilution manufacturer 
Goat anti rabbit IgG 
(H+L) 1 % Blotto in TBS-T 1:20,000 
Dianova, Hamburg, 
Germany 
 
table 1: Primary and secondary antibodies used for Western Blot analysis 
 
3.3.3.3 Semi-Dry blotting 
 
Using a Transblot SD semidry transfer cell (Bio-Rad, Hercules, USA), the separated proteins 
were electrophoretically transferred to a PVDF membrane (Immobilon-P, Millipore, Bedford, 
MA, USA), which was incubated in Methanol for 5 min and then stored for at least 30 min in 
anode buffer before usage. One sheet of thick blotting paper (Schleicher & Schüll) was 
soaked with anode buffer and rolled onto the anode. The prepared membrane and the gels 
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were added. After covering the stack with another sheet of thick blotting paper soaked with 
cathode buffer, the transfer was carried out for 1 h at 1,6 mA/cm2. In order to saturate 
unspecific binding sites, the membrane was immersed for 1 h in 5 % non-fat dry milk in  
TBS-T at RT.  
 
3.3.3.4 Protein detection 
 
Membranes were incubated with the respective primary antibody solution (see table 1) 
overnight at 4°C. After four washing steps (5 min TBS-T, pH 8,0), the suitable secondary 
horseradish peroxidase-labelled antibody was administered for 1 h at RT, followed by four 
additional washing steps (5 min in TBS-T, pH 8,0). All steps regarding the incubation of the 
membrane were performed under constant shaking. For visualizing of proteins, a freshly 
prepared mixture (1:1) of the two detection solutions was added to the membrane for 1 min.  
The appearing chemoluminescence (see figure 10) was detected by exposure of the 
membrane to a X-ray film (Super RX, Fuji, Düsseldorf, Germany) and following development 
with a Curix 60 Developing system (AGFA, Cologne, Germany). 
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figure 10:  Western Blot detection with Luminol 
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3.3.3.5 Coomassie blue staining 
 
Gels were stained after protein transfer with Coomassie brilliant blue G solution for 20 min 
in order to ensure equal protein loading and blotting efficiency. This dye binds non-specific 
to nearly all kinds of proteins under complexation. Afterwards, gels were washed with 
destaining solution for 60 min until proteins appeared as blue bands. 
 
3.3.3.6 Stripping and reprobing 
 
In order to analyze different proteins on the same membrane, primary and secondary 
antibodies from former experiments have to be removed from the membrane. Therefore, 
blots were incubated in stripping buffer at 50°C, shaking for 30 min. After six washing steps 
in TBS-T (5 min, RT), stripping efficiency was confirmed by carrying out another 
development with ECL solution. When removal of antibodies was successful, the membrane 
was blocked again for 1 h with 5 % non-fat dry milk in TBS-T and then incubation with 
antibodies was performed as described in 3.3.3.4. 
3.4 Electro Mobility Shift Assay (EMSA) 
3.4.1 Solutions 
 
Buffer A      Buffer B 
HEPES pH7.9  10 mM    HEPES pH7.9  20 mM  
KCl   10 mM    NaCl   400 mM 
EDTA   0.1 mM    EDTA   1 mM 
EGTA   0.1 MM    EGTA   0.5 mM 
DTT   1mM    Glycerol  25 % 
PMSF   0.5 mM    DTT   1 mM 
       PMSF   1 mM 
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DTT and PMSF were added to the Buffer A and B stock solutions directly before use. 
 
STE buffer pH 7.5 
Tris-HCl  10 mM 
NaCl   100 mM 
EDTA   1mM 
 
5x binding buffer     Gel loading buffer 
Glycerol  20 %    Tris-HCl  250 mM 
MgCl2   5 mM    Bromphenolblue 0.2 % 
EDTA   2.5 mM    Glycerol  40 % 
NaCl   250 mM 
Tris-HCl  50 mm 
 
Reaction buffer      10x TBE pH8.3    
DTT   2.6 mM    Tris   0.89 M  
5x binding buffer 90 %    Boric acid  0.89 M 
gel loading buffer 10 %    Na2EDTA  0.02 M 
 
non-denaturating polyacrylamide gel 
10x TBE  5.3 % 
PAA solution (30 %) 15.8 % 
Glycerol  2.6 % 
TEMED  0.05 % 
APS   0.08 % 
 
3.4.2 Isolation of nuclear protein 
3.4.2.1 Preparation from cells 
 
A549 cells were grown in 6-well plates up to 90 % confluence and were treated as indicated 
in the respective figure legend. Subsequently, cells were washed twice with ice-cold PBS, 
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scraped off in PBS with a rubber cell scraper, centrifuged for 5 min at 1500 rpm and 
resuspended in 400 µl of ice-cold Buffer A for 15 min. Then 25 µl Nonidet P-40 was added 
and after intense vortexing the cell suspension was centrifuged (14,000 rpm, 4°C, 45 sec). 
The nuclear pellet was resuspended under continuous shaking for 15 min at 4°C in Buffer B. 
The nuclear extract was centrifuged (14,000 rpm, 4°C, 5 min) and the supernatant was 
stored in aliquots at -85°C. 
3.4.2.2 Preparation from lung tissue 
 
Lung tissue (approximately 20 mg) was directly homogenized in 300 µl of Buffer A on ice 
with a dounce homogenizer in order to ensure a homogenous suspension. Samples were 
centrifuged at 1,000 rpm at 4°C for 10 min and resuspendend in 300 ml Buffer A, followed by 
addition of 18 µl Nonidet P-40 (NP-40) and careful mixture of samples. After 10 min 
incubation on ice, samples were centrifuged at 14,000 rpm and 4°C for 10 min. 
Subsequently the pellet was resolved and incubated in 50 µl Buffer B by shaking for 30 min 
at 4°C. After another centrifugation step (14,000 rpm, 10 min, 4°C) the supernatant 
containing nuclear proteins was frozen in aliquots at -85°C until usage for EMSA. 
 
3.4.3 Protein determination 
 
Protein concentrations in isolated nuclear fractions were determined by the method of 
Bradford (Bradford, 1976) using coomassie brilliant blue G-250 as indicating dye (see figure 
11). 
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figure 11: Coomassie Brilliant Blue G-250 
 
3.4.4 Radioactive labeling of consensus oligonucleotides 
 
Double-stranded oligonucleotides, containing either the consensus sequence for NF-κB (5’-
AGT TGA GGG GAC TTT CCC AGG C-3’) and AP-1 (5'-CGC TTG ATG AGT CAG CCG 
GAA-3') (Promega, Heidelberg, Germany) were 5’ end-labelled with [γ32P]-ATP 
(3000 Ci/mmol, Amersham, Freiburg, Germany) using T4 polynucleotide kinase (USB, 
Cleveland, USA), which catalyzes the transfer of the terminal phosphate of ATP to the  
5’-hydroxyl termini of the DNA. After incubation of oligonucleotides with T4 polynucleotide 
kinase for 10 min at 37°C, the reaction was terminated by addition of 0.5 M EDTA solution. 
The radioactive labelled DNA was separated from unlabelled DNA by using NucTrap probe 
purification columns (Stratagene, La Jolla, USA). Radioactive oligonucleotides were eluated 
from the column with 70 µl of STE buffer and frozen at -20°C. 
 
3.4.5 Binding reaction and electrophoretic separation 
 
Equal amounts of nuclear protein were incubated for 5 min in a total volume of 14 µl 
containing 2 µg poly(dIdC) and 3 µl reaction buffer at room temperature. Afterwards, 1ml of 
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the radio-labelled oligonucleotide was added. After incubation for 30 min at room 
temperature, the nucleoprotein-oligonucleotide complexes were resolved by gel 
electrophoresis (Mini-Protean 3, Bio-Rad, Munich, Germany) for approximately 70 min at 
100 V on non-denaturating polyacrylamide gels (4.5 %) with 0.25 % TBE as electrophoresis 
buffer. The gel was autoradiographed with an intensifying screen at - 80°C. Signal detection 
and quantification was performed by phosphorimaging (Cyclone Storage Phosphor Screen; 
Canberra-Packard, Dreieich, Germany). 
 
3.5  In vitro phosphorylation by p38 MAPK 
 
Activity of p38 MAPK was examined with an in vitro phosphorylation assay. In this method, 
myelin basic protein (MBP) is used as substrate for p38 MAPK.  
3.5.1 Solutions 
 
Lysis buffer      
Na2EDTA  2 mM   added freshly before use:  
NaCl   137 mM  Activated Na3VO4 2 mM 
Glycerol  10 %   PMSF   2 mM 
Na2P2O7  2 mM   Complete
®  4 %  
Tris-HCl  20 mM   
TritonX-100  1 % 
Na2C3H7O6P  20 mM 
NaF   10 mM 
 
Kinase buffer 
HEPES   20 mM   added freshly before use: 
MgCl2   20 mM   Activated Na3VO4 2 mM 
Na2C3H7O6P  25 mM   DTT   2 mM 
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ATP mix 
Kinase buffer  X* µl 
[γ32P] ATP  10 mCi/ml (3000 Ci/mmol) 
ATP   5 mM 
MgCl2   2 M  
* buffer is added to adjust volume according to number of samples 
 
Laemmli sample buffer  
Tris-HCl 3.125 M 
SDS 20 % 
Glycerol 50 % 
DTT 16 % 
Pyronin Y  0.005 % 
 
3.5.2 Immunoprecipitation 
 
Approximately 30 mg of frozen lung tissue was homogenized in ice-cold lysis buffer with a 
dounce homogenizer and subsequently centrifuged (10,000 rpm, 4°C, 10 min). Protein 
concentrations were determined in the supernatant according the method of Pierce (Smith et 
al., 1985). Equal amounts of protein were incubated with 1.5 µl of anti-p38 polyclonal rabbit 
antibody (Cell signaling, Frankfurt/Main, Germany). After 2 h of incubation, 
immunoprecipitation was performed with protein A agarose (5 µl per probe) shaking 
overnight at 4°C. Then probes were centrifuged (10,000 rpm, 4 min, 4°C) and the 
precipitates were washed three times with lysis buffer and once with kinase buffer. 
 
3.5.3 In vitro phosphorylation assay 
 
After resuspension in 20 µl of kinase buffer, 3 µl of substrate solution containing 1 mg MBP 
dissolved in 300 µl kinase buffer and 10 µl ATP-mix were added. For phosphorylation this 
incubation mixture was incubated at 30°C for 20 min under permanent shaking. Reaction 
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was stopped by adding 6 µl Laemmli buffer and subsequent heating at 90°C for 3 min. 30 µl 
of this reaction mixture were subjected to SDS-PAGE with a 12 % PAA gel at 200 V (for 
details see 3.3.2). Signal detection and quantification was performed by phosphorimaging 
(Cyclone Storage Phosphor Screen; Canberra-Packard, Dreieich, Germany). 
 
3.6 Isolation and characterization of RNA 
 
Total RNA was prepared using RNeasy® Mini Kit (Qiagen, Hilden, Germany) according to 
the manufacturers’ description. Cells were washed with PBS 3 times and lysed in 350 µl 
RNA lysis buffer per 6 well plate. This buffer directly inactivates RNases.  
Total RNA from lungs was isolated by homogenizing approximately 20 mg of lung tissue 
directly in RNA lysis buffer using a Polytron homogenizer (Kinematics, Luzern, Switzerland). 
Prior to RNA isolation with the guanidinium isothiocyanate RNA isolation method using 
RNeasy® mini columns, the lysat was loaded onto a Qiashredder column (Quiagen, 
Germany) in order to ensure a homogenous suspension. Samples for quantification with 
real-time polymerase chain reaction (real-time PCR) were additionally subjected to DNase 
digestion (RNase-free DNase Set, Quiagen, Hilden, Germany) during RNA isolation, 
because real-time PCR is extremely sensitive to smallest amounts of DNA. The purified RNA 
was eluated from the column with 50 µl of RNase free water under low salt conditions. 
Samples were taken for quantification of total RNA and verification of RNA integrity and RNA 
was stored at -85°C. RNA concentration was determined by measuring the absorption at 260 
nm (A260) and 280 nm (A280) (Lambda Bio 20 Photometer, Perkin Elmer, Überlingen, 
Germany). The amount of RNA was calculated from the A260 value, the ratio A260/A280 was 
used to specify the purity of RNA with ideal values between 1.8 and 2.0. Protein 
contaminations would generate high values at 280 nm and therefore the ratio A260/A280 would 
be too low. Integrity of isolated RNA was checked subjecting 1 µg of total RNA to agarose 
gel electrophoresis (see 3.7.4), ethidium bromide staining and densitometric analysis (Kodak 
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Image Station, Kodak, Rochester, USA). The intensity ratio of ribosomal 28S and 18S RNA 
was used for evaluation of RNA integrity. 
 
3.7 Reverse transcription - polymerase chain reaction 
3.7.1 Solutions 
 
10x TBE buffer  
Tris   50 mM 
Boric acid  50 mM 
Na2EDTA  0.5 mM 
 
3.7.2 Primers 
 
All primers were designed with Primer Express 2.0 software (PE Applied Biosystems) and 
obtained from MWG Biotech AG (Ebersberg, Germany). 
 
NPR-A forward (human): 5’-CCT CAA GTC ATC CAA CTG CGT-3’  
NPR-A reverse (human): 5’-GCA TAA ACG GTG TGT CCT TGC-3’ 
 
NPR-C forward (human): 5’-TGC GGC CGA ATG TCA AAT A-3’ 
NPR-C reverse (human): 5’-AGG CCA CAT GAT TTG GAC G-3’ 
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3.7.3 Reverse transcription and polymerase chain reaction 
 
RT-PCR was performed using the Access RT-PCR System Kit (Promega, Mannheim, 
Germany), which  incorporates AMV Reverse Transcriptase (AMV RT) for first strand cDNA 
synthesis and Thermus flavus (Tfl) DNA Polymerase for second strand cDNA synthesis and 
DNA amplification in a single-tube reaction. 1 µg of total RNA was used for RT-PCR in a 
volume of 50 µl containing 1 mM MgSO4, 1x AMV/Tfl reaction buffer, 200 µM of each dNTP, 
1 µM of each primer, upstream and downstream, and AMV RT and Tfl DNA polymerase 
0.1u/ µl each. First strand cDNA synthesis was carried out at 48°C for 45 min and AMV RT 
inactivation for 2 min at 94°C. Subsequently second strand synthesis and PCR amplification 
(94°C for 30 sec, 60°C for 1 min, 68°C for 2 min, 40 cycles) was performed. 
 
3.7.4 Agarose gel electrophoresis 
 
The PCR products were separated by agarose gel (1.2 %) (Seakem LE Agarose, 
BioWhittaker, Rockland, USA) electrophoresis (Owl Seperation Systems, Portsmouth, USA). 
Ethidium bromide was directly added to the agarose gel solution (1.0 µg/ml) and TBE was 
used as electrophoresis buffer. 5 µl of PCR product was subjected to electrophoresis using 
6x blue/orange loading dye and 100 bp DNA ladder (both Promega, Mannheim, Germany) 
and performed for 2 h at 100 V. Bands were visualized with an image station (Kodak Image 
Station, Kodak, Rochester, USA) at 254 nm. 
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3.8 Real time PCR 
 
Real-time polymerase chain reaction (PCR) is a method which is able to monitor the 
progress of DNA amplification. For real-time detection the Taqman® assay system was used.  
In this assay, a fluorescent reporter dye is utilised for visualization of the increasing amount 
of PCR product. The probe is an oligonucleotide which is labelled with a reporter dye at the 
5’ end and with a quencher dye at the 3’ end. There is no detectable fluorescence when the 
probe is intact, because the quencher dye is close enough to the reporter dye. Through an 
additional 5’ → 3’ – exonuclease activity the Taq polymerase cleaves the probe and leads to 
an increase in fluorescence emission. The fluorescent emission is measured at each cycle.  
The first significant increase in fluorescent intensity during the exponential phase of 
fluorescence augmentation correlates with the initial amount of target template. 
Quantification of the results was performed by using hypoxanthine phospho-
ribosyltransferase (HPRT) as a housekeeping gene (Pfaffl, 2001). 
 
3.8.1 Primer and probe 
 
All primers and probes were designed with Primer Express 2.0 software (PE Applied 
Biosystems) and obtained from biomers.net GmbH (Ulm, Germany). 
 
TNF-α  forward  (mouse): 5’-TGG CCT CCC TCT CAT CAG TTC - 3’ 
TNF-α    reverse   (mouse): 5’-TTG GTG GTT TGC TAC GAC GTG – 3’ 
TNF-α    probe   (mouse): 5’-TGG CCC AGA CCC TCA CAC TCA GAT CAT C-3’ 
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ICAM-1  forward    (mouse): 5’-CTG CTG CTT TTG AAC AGA ATG G-3’ 
ICAM-1  reverse  (mouse): 5’-TCT GTG ACA GCC AGA GGA AGT G-3’ 
ICAM-1  probe  (mouse): 5’-AGA CAG CAT TTA CCC TCA G-3’ 
 
HPRT  forward    (mouse): 5’-GTT AAG CAG TAC AGC CCC AAA ATG-3’ 
HPRT    reverse  (mouse): 5’-AAA TCC AAC AAA GTC TGG CCT GTA-3’ 
HPRT    probe  (mouse): 5’-AGC TTG CTG GTG AAA AGG ACC TCT CGA AGT-3’ 
 
3.8.2 Reverse transcription 
 
Reverse Transcription was performed using the DyNAmoTM  Probe 2-Step qRT-PCR Kit 
(Finnzymes, Espoo, Finland) according to the  manufacturers instructions. An amount of 600 
ng of total RNA was subjected to reverse transcription using M-MuLV RNase H- reverse 
transcriptase. There was no need for separate RNase treatment because the RNase H 
activity in the enzyme degrades RNA in the RNA-cDNA hybrid. 
 
3.8.3 Real time PCR 
 
Real-time PCR was performed using the DyNAmoTM Probe 2-Step qRT-PCR Kit (Finnzymes, 
Espoo, Finland) according to the manufacturers instructions. For real time detection the 
Taqman® Assay system was used. 
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3.9 Microscopy 
3.9.1 Antibodies 
 
Primary antibodies Diluted in Dilution manufacturer 
Anti F4/80 
rat anti mouse 0.2 % BSA in PBS 1:100 
Serotec, Düsseldorf, 
Germany 
Anti TNF-α 
Rabbit anti mouse 0.2 % BSA in PBS 1:100 
Endogen, Rockford, 
USA 
Anti p65 polyclonal 
Rabbit anti mouse 0.2 % BSA in PBS 1:100 
Santa Cruz, 
Heidelberg, Germany 
Secondary antibodies Diluted in Dilution manufacturer 
Alexa Fluor 488 (H+L) 
goat anti-rat IgG 0.2 % BSA in PBS 1:400 
Molecular Probes, 
MoBiTec, Göttingen, 
Germany 
Alexa Fluor 647 (H+L) 
chicken anti-rabbit IgG 0.2 % BSA in PBS 1:400 
Molecular Probes, 
MoBiTec, Göttingen, 
Germany 
HOECHST dye 33342 0.2 % BSA in PBS 5 µg per slice 
Sigma, Deisenhofen, 
Germany 
 
table 2:  Antibodies for tissue and cell staining 
 
3.9.2 Staining of A549 cells 
 
A549 cells were grown until confluence on glass coverslips (∅ 12 mm) in 24-well plates and 
treated as indicated in the respective figure legend. Afterwards cells were washed with PBS 
and fixed using a phosphate buffered formaldehyde solution (3 %) for 15 min.  Cells were 
washed three times with PBS and permeabilized with Triton X-100 (0.2 %) for 2 min. After 
washing another three times with PBS, cells were treated with 0.2 % BSA solution for 20 min 
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in order to prevent unspecific binding of the antibodies. Subsequently cells were incubated 
with the primary antibody for 1 h (see table 2 ), washed three times with PBS, and thereafter 
incubated with the secondary antibody (see table 2) and HOECHST dye for 45 min. Cells 
were again washed three times with PBS, embedded in mounting medium (DakoCytomation, 
Hamburg, Germany) and placed onto glass objective slides. 
 
3.9.3 Staining of lung tissue 
 
For analysis of certain proteins in lung tissue, organs were snap-frozen in liquid nitrogen at 
the indicated times and cut into 10-12 µm sections. For staining of alveolar macrophages 
and TNF-α, slices were dried overnight at RT and subsequently fixed in 3 % formaldehyde 
for 15 min. In order to stain alveolar macrohages, an antibody against the murine F4/80 
antigen was used. This 160kD glycoprotein is expressed by murine macrophages. Slices 
were washed three times with PBS and blocked with 1 % BSA for 20 min. This was followed 
by incubation with 100 µl oft the primary antibody (see table 2) for 1 h at RT. After three 
washing steps, Slices were incubated with the corresponding secondary antibody (see table 
2) for 1h and again were washed three times with PBS. Finally, lung sections were covered 
with mounting medium (DakoCytomation GmbH, Hamburg, Germany) and dried overnight. 
 
3.9.4 Confocal laser scanning microscopy 
 
The major difference between conventional microscopy and CLSM is the confocal 
arrangement of an illumination pinhole and a conjugated detector pinhole which ensures that 
only information from the focal plane reaches the detector. Therefore, an up to 1.4x time’s 
higher resolution can be obtained by using CLSM in comparison to conventional microscopy. 
Various lasers with different excitation wavelengths facilitate the colocalisation of different 
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fluorochromes. For analysis of lung tissue and A549 cells an LSM 510 Meta (Zeiss, 
Oberkochen, Germany) was used. 
 
3.9.5 Staining for leukocyte infiltration 
 
Hematoxylin and eosin (HE) staining was performed by Dr. Herbert Meissner (Institute for 
Pathology, University of Munich, Germany) as described previously (Gerwig et al., 2003). 
Leukocyte infiltration was investigated according to morphological characteristics of 
leukocytes. 
 
3.10 Enzyme-linked immunosorbent assay (ELISA) 
3.10.1 TNF-α measurement in mouse blood 
 
Blood samples were centrifuged for 2 min at 4°C at 13,000 rpm to separate the plasma from 
the cellular fraction. Measurement of TNF- by ELISA was performed as described 
previously (Bohlinger et al., 1996) with an OptEIA Mouse TNF- Elisa Set (Mono/Mono) (BD 
Biosciences, Heidelberg, Germany).  
 
3.10.2 TNF-α measurement in whole lung lysates 
 
TNF- was determined on supernatants of lung homogenates by ELISA as described in 
3.10.1. Supernatants of lung homogenates were obtained as described previously (Mueller 
et al., 2004). 
 
Materials and methods 
55 
3.11 Flow cytometry 
 
Flow cytometry is a technique to analyze suspended individual cells in order to detect 
fluorescent stains. Cells flow through a focused laser beam in a laminar fluid stream.  
According to their size, granularity and stain intensity the incident laser beam is scattered 
and fluorescence can be measured.  
 
3.11.1 Solutions 
 
FACS buffer pH 7.37 
NaCl   138.95 mM 
KH2PO4  1.91 mM 
Na2HPO4  16.55 mM 
KCl   3.76 mM 
LiCl   10.14 mM 
NaN3   3.08 mM 
Na2EDTA  0.967 mM 
 
3.11.2 Preparation and staining of cells 
 
Cells were grown until 90 % confluence in 24-well plates and were treated as indicated in the 
respective figure legend. Afterwards A549 where incubated with 100 µl T/E solution per well 
for 2 min at 37°C. The cells where gradually detached and the digestion of trypsin was 
stopped by transferring the cells into FACS tubes containing phosphate buffered 
formaldehyd solution (10 %) and incubating them for 15 min. Subsequently, cells were 
washed with PBS and incubated with a flurescent dye-labelled antibody against ICAM-1 
(FITC-labelled mouse anti human CD54 IgG1, Biozol, Eching, Germany) in the dark for  
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20 min. After washing, cells were resuspended in PBS for flow cytometric analysis 
(FACSCalibur, BD Biosciences, Heidelberg, Germany). 
3.12 Statistics 
 
All experiments were performed at least three times unless indicated otherwise in the 
respective figure legend. Results were expressed as mean ± SEM. Statistical analysis was 
performed with GraphPad Prism 3.03 (GraphPad Software Inc. San Diego, USA). ANOVA 
with Bonferroni multiple comparison post-test for comparison of three or more groups or 
unpaired two-tailed Student t-test for comparison of two groups were used. 
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4 Results 
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4.1 Alveolar epithelial cells 
 
4.1.1 A549 alveolar epithelial cells express NPR-A and NPR-C 
 
Expression of natriuretic peptide receptors in alveolar epithelial cells in vivo and in primary 
isolated alveolar epithelial cells has been described previously (Tharaux et al., 1998). 
However, there existed no data concerning the expression of these receptors in the human 
alveolar epithelial cell line A549 which we meant to use for these initial experiments. 
Therefore, we carried out RT-PCR for NPR-A and NPR-C, the major receptors ANP binds to. 
Due to the fact that expression of NPR-A and NPR-C in endothelial cells has been described 
previously (Inagami et al., 1995), human umbilical vein endothelial cells (HUVECs) were 
used as positive control. RT- PCR experiments revealed the presence of both NPR-A and 
NPR-C mRNA in A549 alveolar epithelial cells (see figure 12). 
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figure 12 A549 alveolar epithelial cells express NPR-A and NPR-C 
  RNA from A549 alveolar epithelial cells and from HUVECs, used as  
  positive control (+), was isolated as described in 3.5. Afterwards, 1 µg of total 
  RNA was subjected to RT-PCR and subsequent agarose gel electrophoresis 
  (M = marker) (see 3.7 for details).  
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4.1.2 Influence of ANP on TNF-α induced NF-κB activation  
 
ANP was shown to diminish TNF-α induced activation of pro-inflammatory transcription 
factors in endothelial cells (Kiemer et al., 2002e). NF-κB is one of the most important 
mediators regarding TNF-α mediated signalling. In order to determine a possible anti-
inflammatory activity of ANP on alveolar epithelial cells, we examined the effects of ANP on 
TNF-α induced DNA binding activity of NF-κB with EMSA. 
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figure 13 ANP pretreatment inhibits TNF-α induced NF-κB binding activity  
 Cells were either left untreated or were pretreated with ANP (10-6M) for 15 min. 
 Where indicated, cells were treated with TNF-α (10 ng/ml) for 15 min. 
 NF-κB DNA binding activity was measured by EMSA as described in 3.4. 
 
 
TNF-α already caused increasing levels of NF-κB DNA complex as soon as 15 min. 
Pretreatment of epithelial cells with 10-6 M ANP markedly reduced this NF-κB DNA binding 
activity as shown in figure 13. Sole treatment with ANP had no effect on NF-κB activation 
(data not shown). Specificity of DNA-complex was confirmed by competition with a 100-fold 
excess of unlabelled NF-κB (positive control) and AP-1(negative control) binding sequences 
(data not shown). 
Next we performed immunohistochemistry of the p65 subunit of NF-κB in order examine 
whether the diminished NF-κB DNA binding activity observed by EMSA is associated with a 
reduced translocation of NF-κB into the nucleus. A549 cells were investigated by staining of 
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the p65 subunit in TNF-α treated and ANP preconditioned cells and analyzing them by 
confocal microscopy. 
Co
TNF
ANP + TNF
 
 
figure 14 Influence of ANP on TNF-α induced translocation of p65 
  A549 cells were treated with TNF-α (10 ng/ml) for 30 min or left untreated (Co). 
Where indicated, cells received pretreatment with ANP (10-6 M) for  
15 min. Subsequently cells were stained for p65 and nuclei as described in 
3.9.2 and CLSM was performed as described in 3.9.4. 
 Blue: nuclei, red: p65 
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TNF-α treatment (10 ng/ml) leads to p65 translocation into the nuclei of alveolar epithelial 
cells compared to untreated cells, were p65 remained in the cytoplasm. Preconditioning with 
ANP (10-6 M) resulted in a reduced number of cells with translocated p65. 
4.1.3 Influence of ANP on TNF-α induced AP-1 activation  
 
Another major transcription factor mediating TNF-α induced pro-inflammatory events is the 
activator protein-1. Because AP-1 is activated by TNF-α in our cell model, we investigated 
the property of ANP pretreatment to reduce AP-1 binding to DNA in the nucleus by EMSA. 
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figure 15 Preconditioning with ANP reduces TNF-α induced AP-1 induction 
 Cells were either left untreated or were pre-treated with ANP (10-6M) for 15  min. 
 Where indicated, cells were treated with TNF-α (10 ng/ml) for 15 min. 
 AP-1 DNA binding activity was measured by EMSA as described in 3.4 
 
 
 
Treatment of A549 cells with TNF-α (10 ng/ml) markedly induced AP-1 DNA binding activity 
after 15 min. Administration of ANP (10-6 M) 15 min prior to TNF-α treatment resulted in 
reduced levels of AP-1 DNA complex detected by EMSA. Specificity of DNA-complex was 
confirmed by competition with a 100-fold excess of unlabelled AP-1 (positive control) and 
NF-κB (negative control) binding sequences (data not shown). 
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4.1.4 Effects of ANP on TNF-α induced ICAM-1 expression 
 
The adhesion molecule ICAM-1 has a prominent role in orchestrating epithelial inflammation. 
NF-κB and AP-1 both strongly participate in regulation of TNF-α dependent ICAM-1 
transcription. Therefore, we examined the influence of ANP pretreatment on  
TNF-α mediated ICAM-1 expression by flow cytometry.  
ICAM-1 surface expression was significantly induced by TNF-α (10 ng/ml and 2 ng/ml) as 
shown in figure 16. Protein expression was already detectable after 2 h of TNF-α treatment 
and increased steadily up to 24 h. ANP pretreatment did not effect TNF-α induced ICAM-1 
expression 
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figure 16 No effect of ANP on TNF-α induced ICAM-1 expression 
 Cells were treated with TNF-α (10 ng/ml or 2 ng/ml) with or without 15 min 
 preconditioning with ANP (10-6 M) for 24 h, 8 h or 2 h. After the indicated times 
 cells were harvested and stained afterwards with FITC-labelled ICAM-1 
 antibody for flow cytometry (see 3.11). **p ≤0.01 vs. Co 
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4.2 Effects of ANP during LPS-induced septic shock in 
the murine lung 
 
In order to investigate the potential in vivo relevance of our findings, we investigated the 
effects of ANP in a murine model of septic shock with special focus on the lung.  
 
After treatment of mice and lethal anaesthesia as described in 3.2.3.2, we examined in the 
lung two major transcription factors NF-κB and AP-1, which are known to have a major 
impact on inflammatory processes. 
 
4.2.1 Effects of ANP preconditioning on NF-κB binding activity 
 
NF-κB has great importance in LPS mediated signalling (see2.5) Therefore, we investigated 
the DNA binding activity of this transcription factor in the lung. In the NaCl treated control 
group only basal levels of NF-κB binding activity were detectable. Treatment with ANP alone 
had also no effect on this transcription factor. As shown in figure 17, LPS treatment caused 
a marked increase in NF-κB DNA binding activity after 15 min and 30 min LPS challenge. 
Interestingly, preconditioning with ANP was able to protect the lung from this increase and 
caused a remarkable lowering of binding activity. This decline was detectable 15 min after 
LPS challenge and increased further 30 min after LPS administration. Specificity of DNA-
complex was confirmed by competition with a 100-fold excess of unlabelled AP-1(positive 
control) and NF-κB (negative control) binding sequences (data not shown). 
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figure 17 Preconditioning with ANP leads to a reduction of LPS-induced NF-κB 
binding activity after 15 and 30 min. Animals were injected intravenously with 
either NaCl (Co) or ANP (5 µg/kg b.w.) 15 min prior to i.p. LPS challenge  
(1 mg/kg b.w.). or NaCl (0.9 %) injection. Co: NaCl treated i.v.; ANP: ANP i.v. 
after 15 min NaCl i.v.; LPS: NaCl i.v., after 15 min LPS i.p.; ANP + LPS: ANP 
i.v., 15 min later LPS i.p.. Lungs were excised 15 min or 30 min after LPS 
injection, snap-frozen in liquid nitrogen, homogenized and investigated by 
EMSA as described in 3.4.. Results show one representative EMSA out of two 
experiments (four lungs in each treatment group). 
 
 
4.2.1.1 Effects of ANP on phosphorylation and degradation of IκBα 
 
Having observed an influence of ANP on LPS-induced NF-κB translocation, we were now 
interested in the possible upstream mechanism responsible for ANP-mediated inhibition of 
NF-κB. Phosphorylation and subsequent proteasomal degradation if the cytoplasmatic 
inhibitor of NF-κB protein α (IκBα) is a deciding event in LPS-induced NF-κB activation (see 
figure 7). In order to determine a possible effect of ANP on phosphorylation and degradation 
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of IκBα we performed Western Blot analysis as described in 3.3.3 for phosphorylated and 
non-phosphorylated forms of IκBα.  
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figure 18 ANP pre-treatment reduces LPS-induced IκBα phosphorylation and 
induces total IκBα protein levels.  Animals were injected intravenously with 
either NaCl (Co) or ANP (5 µg/kg b.w.) 15 min prior to i.p. LPS challenge 
(1mg/kg b.w.). or NaCl (0.9 %) injection. Co: NaCl treated i.v.; ANP: ANP i.v. 
after 15 min NaCl i.v.; LPS: NaCl i.v., after 15 min LPS i.p.; ANP + LPS: ANP 
i.v., 15 min later LPS i.p.. Lungs were excised 15 min 30 after LPS or NaCl 
injection, snap-frozen in liquid nitrogen, homogenized and investigated by 
Western Blot as described in3.3. Representative Western Blots with two lungs 
out of five are shown. * p ≤ 0.05 vs. NaCl. 
 
 
There were no detectable levels of phosphorylated IκBα protein in the control and ANP 
treated group of animals (figure 18). Phosphorylated IκBα protein occurred after 15 min in 
LPS treated mice. This phosphorylation was slightly reduced in ANP preconditioned mice. 
Degradation of IκBα was not yet detectable after 15 min. Astonishingly elevated levels of 
total IκBα protein could be detected in animals who received only ANP. 
Degradation of IκBα occurred 30 min after LPS administration as shown in figure 19. In 
contrast, administration of ANP prior to LPS caused only a slight reduction of IκBα protein 
levels. 
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figure 19 Preconditioning with ANP leads to a reduction of LPS-induced 
degradation of IκBα 30 min after LPS injection. Animals were injected 
intravenously with either NaCl (Co) or ANP (5 µg/kg b.w.) 15 min prior to i.p. 
LPS challenge (1 mg/kg b.w.) or NaCl (0.9 %) injection. Co: NaCl treated i.v.; 
ANP: ANP i.v. after 15 min NaCl i.v.; LPS: NaCl i.v., after 15 min LPS i.p.; ANP 
+ LPS: ANP i.v., 15 min later LPS i.p.. Lungs were excised 30 min after LPS 
injection, snap-frozen in liquid nitrogen, homogenized and investigated by 
Western Blot as described in 3.3. Representative Western Blots with two lungs 
out of five are shown. * p ≤ 0.05 vs. NaCl. 
 
 
 
4.2.2 ANP effects on AP-1 DNA binding activity 
 
Another major transcription factor, which is involved in LPS-induced pro-inflammatory 
pathways, is the activator protein-1. Our previous experiments with alveolar epithelial cells 
(see 4.1.3) revealed a commanding potency of ANP to influence this pathway. On this 
account, we investigated the AP-1 DNA binding activity in mouse lung at different time-
points.  
Basal AP-1 DNA binding activity was low in control animals. 15 min after LPS administration, 
no detectable levels of AP-1 were found in the lung (data not shown). DNA binding activity 
increased after 30 min in LPS treated animals vs. animals in the control group as illustrated 
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in figure 20. ANP alone did not alter AP-1 DNA complex in the nucleus. Preconditioned 
animals showed a remarkable reduction in AP-1 DNA binding activity at this point in time. 
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figure 20 ANP pretreatment leads to a reduction of LPS-induced AP-1 binding 
activity after 30 min. Animals were injected intravenously with either NaCl (Co) 
or ANP (5 µg/kg b.w.) 15 min prior to i.p. LPS challenge (1 mg/kg b.w.) or NaCl 
(0.9 %) injection. Co: NaCl treated i.v.; ANP: ANP i.v. after 15 min NaCl i.v.; 
LPS: NaCl i.v., after 15 min LPS i.p.; ANP + LPS: ANP i.v., 15 min later LPS 
i.p.. Lungs were excised 30 min after LPS injection, snap-frozen in liquid 
nitrogen, homogenized and investigated by EMSA as described in 3.4.Results 
show one representative EMSA out of two experiments (four lungs in each 
treatment group). 
 
 
 
4.2.3 Influence of ANP on p38 MAPK in LPS treated lung 
 
In order to clarify the possible mechanism by which ANP impairs LPS-induced lung 
inflammation, we investigated two possible pathways. Several mitogen activated kinases 
(MAPK) have been described to participate in LPS mediated signalling. As summarized in 
figure 7 and 2.6, the p38 MAPK is involved in the signal transduction of LPS leading to 
activation of the transcription factors NF-κB and AP-1. On this account, we examined a 
possible role of p38 MAPK in ANP-mediated inhibition of this transcription factors in LPS-
induced lung injury first.  
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4.2.3.1 Activation of p38 MAPK in LPS-induced lung inflammation 
The time course shown in figure 21 demonstrates increasing p38 MAPK activation in 
response to LPS in murine lung. MAPK activation was detected by immunoblotting with 
phospho-specific antibodies (see 3.3.3). This activation occurred very fast peaking already at 
15 min after LPS administration and is still detectable after 90 min. 
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figure 21  LPS treatment  provokes p38 MAPK phosphorylation in the lung 
 Animals received an i.v. injection of NaCl 0.9 % (Co) or i.p. injection of LPS  
(1 mg/kg b.w.). Lungs were excised at the indicated time points, snap-frozen in 
liquid nitrogen, homogenized and investigated by Western Blot as described in 
3.3. ** p  ≤ 0.01 vs. Co and * p ≤ 0.05 vs Co. 
 
 
4.2.3.2 ANP effects on LPS-induced p38 MAPK activation 
 
Basal levels of phosphorylated p38 MAPK are low in NaCl and ANP treated animals.  
Pretreatment with ANP was able to reduce significantly LPS-induced activation of  
p38 MAPK in lung injury as shown by Western Blot (figure 22). Interestingly, ANP alone 
seemed to slightly elevate p38 MAPK phosphorylation in comparison to the NaCl group. 
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figure 22  ANP pretreatment minors LPS-induced phosphorylation of p38 MAPK 
Animals were injected intravenously with either NaCl (Co) or ANP (5 µg/kg b.w.) 
15 min prior to i.p. LPS challenge (1 mg/kg b.w.) or NaCl (0.9 %) injection. Co: 
NaCl treated i.v.; ANP: ANP i.v. after 15 min NaCl i.v.; LPS: NaCl i.v., after 15 
min LPS i.p.; ANP + LPS: ANP i.v., 15 min later LPS i.p.. Lungs were excised 
15 min after LPS injection, snap-frozen in liquid nitrogen, homogenized and 
investigated by Western Blot as described in 3.3. One representative Western 
Blot out of two with four lungs in each treatment group is shown. 
 
4.2.3.3 Influence of ANP treatment on p38 MAPK activation 
 
First data indicated a possible influence of ANP treatment on basal p38 MAPK activation. 
Furthermore, protective effects of ANP via activation of p38 MAPK have been described 
previously in ischemia reperfusion injury in the liver. Therefore, we aimed to investigate the 
effect of ANP treatment on p38 MAPK activation in the lung.  
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figure 23 Effect of ANP treatment on p38 MAPK phosphorylation in the lung 
 Animals received an i.v. injection of NaCl 0.9 % (Co) or i.v. injection of ANP (5 
µg/kg b.w.). Lungs were excised at the indicated time points, snap-frozen in 
liquid nitrogen, homogenized and investigated by Western Blot as described in 
3.3. ** p  ≤ 0.01 vs NaCl. 
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As shown in figure 23, Western Blot analysis of dual phosphorylated p38 MAPK revealed a 
distinct increase in p38 MAPK phosphorylation after 15 min ANP treatment. This effect is still 
noticeable 30 min and 45 min after ANP administration and is abrogated after 105 min. In 
order to corroborate this effect we examined the in vitro phosphorylation activity by p38 
MAPK in ANP treated lungs. figure 24 shows that ANP treatment of mice is able to increase 
the phosphorylation activity of ANP in the lung. 
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figure 24 Effect of ANP on in vitro phosphorylation activity by p38 MAPK 
 Animals received an i.v. injection of NaCl 0.9 % (Co) or i.v. injection of ANP (5 
µg/kg b.w.). Lungs were excised at the indicated time points, snap-frozen in 
liquid nitrogen, homogenized and investigated by in vitro phosphorylation assay 
by p38 MAPK as described in 3.5.  
 
 
4.2.4 Influence of Akt kinase in LPS treated lung 
 
As a second possible pathway involved in ANP-mediated reduction of NF-κB and AP-1 
activation in lung inflammation, we led our interest on the protein kinase Akt, also known as 
protein kinase B (PKB). New insights in LPS-mediated signal transduction revealed a major 
role in regulating the response to pro-inflammatory stimuli.  
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4.2.4.1 Activation of Akt in LPS-induced lung inflammation 
 
First, we wanted to examine potential effects of LPS on Akt activation during murine sepsis 
in the lung. Therefore, immunoblotting was performed for the phosphorylated form of Akt as 
described in 3.3.3. figure 25 demonstrates that activation of Akt occurred after 15 min in 
LPS-induced lung injury and lasted until 90 min after LPS administration.  
Co 15 min 30 min 90 min 
0
1
2
3
4
5
*
*
 ¢¡£ ¤
¥¦
§ ¨
©ª«
¬­«
¤£ ®
¡
±² ³

 
 
figure 25 Akt phosphorylation occurs in the lung after LPS challenge 
 Animals received an i.v. injection of NaCl 0.9 % (Co) or i.p. injection of LPS 
 (1 mg/kg b.w.). Lungs were excised at the indicated time points, snap-frozen in 
liquid nitrogen, homogenized and investigated by Western Blot as described in 
3.3. * p ≤ 0.05 vs. Co 
 
 
4.2.4.2 ANP effects on Akt activation 
 
Now we were interested in possible effects of ANP regarding LPS-induced Akt activation. 
As illustrated in figure 26, ANP pretreatment was able to reduce LPS-induced Akt 
phosphorylation. ANP administration alone also seemed to increase Akt activation in the 
lung. 
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figure 26 Preconditioning with ANP leads to a reduction of LPS-induced 
phosphorylation of Akt after 15 min. Animals were injected intravenously with 
either NaCl (Co) or ANP (5 µg/kg b.w.) 15 min prior to i.p. LPS challenge  
(1 mg/kg b.w.) or NaCl (0.9 %) injection. Co: NaCl treated i.v.; ANP: ANP i.v. 
after 15 min NaCl i.v.; LPS: NaCl i.v., after 15 min LPS i.p.; ANP + LPS: ANP 
i.v., 15 min later LPS i.p.. Lungs were excised 30 min after LPS injection, snap-
frozen in liquid nitrogen, homogenized and investigated by Western Blot as 
described in 3.3. One representative Western Blot out of two with four lungs in 
each treatment group is shown. 
 
 
4.2.5 Expression of ICAM-1 
 
ICAM-1 is upregulated in response to LPS, TNF-α and other inflammatory mediators 
occurring in the lung during infection. NF-κB and AP-1, which were shown to be influenced 
by ANP, have major impact on regulating ICAM-1 expression. On this account, we 
investigated expression of ICAM-1 in the lung of LPS treated mice and the influence of ANP 
preconditioning on this important initial process. LPS treatment increases ICAM-1 mRNA 
expression in mouse lung, beginning after 30 min and accelerating after 90 min. As shown in 
figure 27, ANP preconditioning was able to reduce ICAM-1 mRNA expression at early points 
in time, but no difference concerning mRNA expression could be observed 90 min after LPS 
treatment. 
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figure 27 ANP pretreatment mildly decreases ICAM-1 expression during 
endotoxaemia after 30min. No difference in expression levels can be 
observed after 90 min Animals were injected intravenously with either NaCl 
(Co) or ANP (5 µg/kg b.w.) 15 min prior to i.p. LPS challenge (1 mg/kg b.w.) or 
NaCl (0.9 %) injection. Co: NaCl treated i.v.; LPS: NaCl i.v., after 15 min LPS 
i.p.; ANP + LPS: ANP i.v., 15 min later LPS i.p.. Lungs were excised 30 min and 
90 min after LPS injection and snap-frozen in liquid nitrogen. RNA was 
extracted and Real-time PCR was performed as described in 3.7. 
 
4.2.5.1 Leukocyte infiltration 
 
Infiltration of leukocytes into the alveolar space is an important process regarding 
inflammatory processes in the lung. A major requirement for this event is the expression of 
adhesion molecules like ICAM-1 in vascular endothelium and respiratory epithelium, in which  
ANP has shown to be able to interfere. Therefore, we investigated lungs after 30 min and  
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90 min LPS treatment. At the indicated time points, we were not able to detect any signs of 
leukocyte infiltration into the alveolar space. 
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figure 28: Leukocyte infiltration 30 und 90 min (100x) Animals were injected 
intravenously with either NaCl (Co) 15 min prior to i.p. LPS challenge (1 mg/kg 
b.w.). or NaCl (0.9 %) injection. Co: NaCl treated i.v.; LPS: NaCl i.v., after 15 
min LPS i.p.; Lungs were excised 30 min and 90 min after LPS injection, stored 
in formalin and embedded in paraffin. Slices were stained with haematoxylin 
and eosin (for details see 3.9.5). 
 
4.2.6 TNF-α in LPS-induced lung inflammation 
 
TNF-α is an important pro-inflammatory cytokine produced by various cells types, which has 
an outstanding role in the onset of sepsis. Because the NF-κB pathway is the predominant 
pathway in regulating the transcription of TNF-α, we were now interested in the effects of 
ANP regarding LPS-induced TNF-α expression in our model of sepsis. 
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4.2.6.1 Influence of ANP on serum levels and whole lung expression  
of TNF-α  
 
The following animal experiments were kindly performed by Dr. Martin Lehner (Biochemical 
Pharmacology, University of Konstanz). 
In order to investigate a potential effect of ANP on serum TNF-α levels, mice were pretreated 
with different doses of ANP 15 min prior to LPS administration (see figure 29) and plasma 
TNF-α levels of TNF-α were obtained by ELISA as described in 3.10. As illustrated in  
figure 29, ANP preconditioning dramatically reduced LPS-induced TNF-α serum levels in 
each administered concentration.  
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figure 29 ANP preconditioning perspicuously diminishes TNF-α serum levels in a 
murine model of sepsis. Animals were injected i.p. with either NaCl (Co) or 
ANP (50 µg/kg b.w., 5 µg/kg b.w. or 0.5 µg/kg b.w.) prior to i.p. LPS 
administration (300 µg/kg b.w.). After 120 min heart blood was obtained and 
ELISA was performed as described in 3.2.3.1 and 3.10.1 .** p ≤ 0.01 vs. Co 
 
Next we wanted to examine whether ANP has also an effect on TNF-α protein levels in the 
lung. Therefore, lungs were excised after the indicated times (for detail see figure 30) and 
ELISA was performed in whole lung lysates (3.10.2). ANP pretreatment showed only a minor 
reduction of LPS-induced TNF-α expression in the whole murine lung as shown in figure 30. 
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figure 30 TNF-α levels in whole lung lysates of mice being pre-treated with ANP are 
mildly reduced in comparison to lung lysates of mice which only received 
LPS. Animals were injected i.v. with either NaCl (Co) or ANP (50 µg/kg b.w., 5 
µg/kg b.w. or 0.5 µg/kg b.w.) prior to i.p. LPS administration (300 µg/kg b.w.). 
After 120 min lungs were excised and ELISA was performed as described in 
3.10.2 . * p ≤ 0.05 vs. Co 
 
 
4.2.6.2 Localisation of TNF-α in LPS-induced lung inflammation 
 
Several cell types in the lung have been described being able to produce pro-inflammatory 
mediators like cytokines. In order to determine, which cell type in the lung is involved in  
TNF-α expression in our model, and if ANP may have a effect on TNF-α expression in these 
cells, lung tissue was stained for TNF-α and for the F4/80 antigen expressed by 
macrophages. As shown in figure 31, intracellular TNF-α could be detected after 90 min in 
LPS treated lungs. Co-staining of macrophages revealed that TNF-α seems to be expressed 
primarily in alveolar macrophages. There was no detectable difference in TNF-α expression 
between LPS treated lungs and lungs, which received ANP preconditioning. 
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figure 31  TNF-α expressing cells in murine lung during LPS-induced sepsis Animals 
were injected intravenously with either NaCl (Co) 15 min prior to i.p. LPS 
challenge (1 mg/kg b.w.) or NaCl (0.9 %) injection. Co: NaCl treated i.v.; LPS: 
NaCl i.v., after 15 min LPS i.p.; Lungs were excised 30 min and 90 min after 
LPS injection and snap-frozen in liquid nitrogen. Slices were stained and CLSM 
was performed as described in3.9.3 and 3.9.4. 
Blue: nuclei, green: alveolar macrophages, magenta: TNF-α 
 
4.2.6.3 Effects of ANP on LPS-induced TNF-α expression  
 
In previous experiments (see 4.2.6.1), ANP slightly decreased TNF-α measured in whole 
lung lysates. In order to investigate this observation in our model of murine sepsis, lung 
tissue was investigated with real-time PCR for TNF-α expression.  
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Basal levels of TNF-α were extremely low in control animals. LPS administration rapidly 
induced TNF-α mRNA expression in the lung after 30 min and is still there 90 min after LPS 
administration as shown in figure 32. ANP showed no significant effect on TNF-α mRNA 
expression in our model of murine sepsis. After 30 min, a slight but not significant reduction 
of TNF-α mRNA could be observed. This minor decrease could not be detected after 90 min 
of LPS treatment. 
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figure 32 ANP has no significant effect on TNF-α expression in endotoxaemia 
Animals were injected intravenously with either NaCl (Co) or ANP (5 µg/kg b.w.) 
15 min prior to i.p. LPS challenge (1 mg/kg b.w.) or NaCl (0.9 %) injection. Co: 
NaCl treated i.v.; LPS: NaCl i.v., after 15 min LPS i.p.; ANP + LPS: ANP i.v., 15 
min later LPS i.p.. Lungs were excised 30 and 90 min after LPS injection and 
snap-frozen in liquid nitrogen. RNA was extracted and Real-time PCR was 
performed as described in 3.7. 
 ** p ≤ 0.01 vs. NaCl 
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5 Discussion 
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5.1 Alveolar epithelial cells 
 
5.1.1 A549 alveolar epithelial cells express NPR-A and NPR-C 
 
In the year 1977, Mason and Williams postulated the concept of alveolar type II cells being a 
defender of the alveolus (Mason and Williams, 1977). Today it is well known, that synthesis, 
secretion and recycling of pulmonary surfactant, and thereby regulation of pulmonary 
tension, is not the only important function of these cells. These cells have also important 
functions in maintaining alveolar fluid balance, coagulation, fibrinolysis and host defence. 
Additionally, they crucially contribute to epithelial tissue repair by their ability to differentiate 
to alveolar type I cells, which form the epithelial component of the thin-air-blood barrier 
(reviewed in (Fehrenbach, 2001)).  Nowadays it is well established, that the lung is not only 
an extra-atrial source of ANP, but that it also expresses all three natriuretic peptide receptors 
(Perreault and Gutkowska, 1995). Radioautographic localisation of 125I-ANP after infusion 
revealed high-end-labelling in the lung particularly in alveolar epithelial cells (Geary et al., 
1993). In addition, activation of particulate GC could be observed morphologically with 
electron microscopy in rat alveolar type II cells (Rambotti and Spreca, 1991). These studies 
indicate the presence of NPR-A and NPR-B receptors in these cells. Recent studies showed 
the presence of functional NPR-A und NPR-B, but not the clearance receptor NPR-C in 
cultured rat alveolar type II cells (Tharaux et al., 1998). Interestingly, in another study ANP 
was shown to induce a dose dependent accumulation of cGMP, reduced ligand stimulated 
adenylyl cyclase activity and prevented cAMP accumulation in isolated rat alveolar type II 
cells. Moreover, ANP inhibited surfactant secretion in these experiments (Panchenko et al., 
1998). The observed reduction of cAMP accumulation suggests the presence of a functional 
NPR-C receptor. This observation disagrees wtih the findings of Tharaux and co-workers. 
The human cell line A549 is one of the best characterised alveolar epithelial type II cell lines 
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and is routinely used for many experiments concerning the alveolar epithelium in response to 
inflammatory stimuli. Stimulation of  these cells with ANP lead to a significant increase in 
intracellular cGMP and subsequent transforming growth factor β (TGF-β) release (Bellocq et 
al., 1999), but up to now no reports have been published verifying the presence of natriuretic 
peptide receptors in these cells. Investigating isolated mRNA from these cells, we were able 
to reveal the expression of natriuretic peptide receptor A and natriuretic peptide receptor C in 
A549 cells (figure 12). Because we focused our interest on possible effects of one natriuretic 
peptide, ANP, natriuretic peptide receptor B (NPR-B), which preferably binds CNP, was not 
investigated. 
 
5.1.2 ANP reduces TNF-α induced NF-κB activation  
 
In the last thirty years increasing evidence pictures the alveolar epithelium as a dynamic 
barrier, which plays an important role in the regulation of inflammatory and metabolic 
responses to oxidative stress, sepsis and other critical illnesses in the lung (Matthay et al., 
2005). The respiratory epithelium is a primary target of inflammatory processes at the blood-
epithelial interface, and in addition is able to modulate and amplify inflammatory signals by 
producing inflammatory mediators such as IL-8, MCP-1 or ICAM-1 (Fehrenbach, 2001; dos 
Santos et al., 2004). The inflammatory cytokine TNF-α was shown to induce a potent 
inflammatory answer in alveolar epithelial cells, leading to activation of several important 
transcription factors in the inflammatory response including NF-κB. This pro-inflammatory 
transcription factor is rapidly activated after stimulation and regulates the expression of a 
variety of genes encoding crucial mediators in inflammation. NF-κB is a heterodimer, which 
consists of two subunits, p50 and p65. In unstimulated cells it is bound to its inhibitory 
protein IκBα, which keeps NF-κB in the cytoplasm and inhibits its translocation into the 
nucleus by masking the nuclear localisation sequence (NLS) (Baud and Karin, 2001).  
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The result of the present work shows, that ANP is able to reduce TNF-α induced  
NF-κB DNA binding activity in alveolar epithelial cells (figure 13). Moreover, we investigated 
the translocation of the p65 subunit of NF-κB and demonstrated that this effect is caused by 
a decreased translocation of p65 into the nucleus in response to TNF-α stimulation  
(figure 14). Previous experiments in our laboratory revealed that ANP is able to inhibit TNF-α 
induced activation of NF-κB in human umbilical vein endothelial cells and several 
macrophages as well (Kiemer et al., 2000a; Kiemer et al., 2002a; Kiemer et al., 2002e), 
therefore supporting our findings. Additionally, reduced NF-κB DNA binding activity was also 
accompanied by a decreased p65 nuclear translocation in those experiments. By affecting 
an essential transcription factor in TNF-α signalling, this is the first report that ANP may have 
direct anti-inflammatory properties on lung epithelium. Interestingly, Hellermann and 
coworkers reported recently that a novel, plasmid encoded unphysiological C-terminal 
natriuretic peptide which consists of aa 73-102, inhibited TNF-α induced NF-κB activation in 
alveolar epithelial cells as well.  
 
5.1.3 ANP inhibits TNF-α induced AP-1 activity  
 
Activator protein-1 (AP-1) is an important transcription factor acting as an environmental 
biosensor to various external stimuli and regulates gene expression in a variety of biological 
processes such as proliferation, differentiation and inflammatory processes. Being a  
homo- or heterodimer, it is mainly composed of Jun-Jun or Jun-Fos proteins. AP-1 activity in 
response to external stimuli can be influenced by both regulating the transcription of jun and 
fos genes, and posttranslational modifications, such as the phosphorylation of cJun 
(Shaulian and Karin, 2002). The posttranslational impact on AP-1 activation in response to 
pro-inflammatory cytokines is mainly mediated by two MAPK cascades, JNK and p38 MAPK 
(Chang and Karin, 2001). Alveolar epithelial cells have been described to show an increased 
DNA-binding activity of AP-1 in response to TNF-α. Furthermore, recent studies propose an 
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involvement of glutathione oxidation and subsequent histone acetylation in TNF-α induced 
AP-1 activation in this special cell type (Rahman et al., 2002).  
Being a major transcription factor involved in inflammation of lung epithelium (Rahman, 
2000; Rahman et al., 2002), we investigated possible effects of ANP on TNF-α induced AP-1 
DNA binding activity. As demonstrated in the present work, ANP is able to inhibit TNF-α 
induced AP-1 activity in human alveolar epithelial cells (figure 15). Former investigations 
showed varying results regarding inhibitory actions of ANP on this transcription factor. In 
LPS activated mouse bone marrow macrophages as well as in ischemia reperfusion injury in 
the rat liver ANP was capable to reduce AP-1 DNA binding activity, and thereby mediating 
protective effects such as minor TNF-α expression (Kiemer et al., 2000b; Kiemer et al., 
2000a). In HUVECs, however, ANP had no influence on TNF-α induced AP-1 activation 
(Kiemer et al., 2002e). These data point out, that ANP is able to influence AP-1 activation in 
several species, but this property seems to be a cell type specific event. 
 
5.1.4 ANP does not alter TNF-α induced ICAM-1 expression 
 
Inflammatory cytokines such as TNF-α are able to induce expression of adhesion molecules 
in alveolar epithelium. This can be regarded as a crucial step in the orchestration of lung 
inflammation, because an augmented expression of adhesion molecules is indispensable for 
recruitment of leukocytes to sites of infection (Beck-Schimmer et al., 2004). In addition, 
recent studies revealed, that ICAM-1 is able to co-stimulate target cells to facilitate antigen 
presentation (Lebedeva et al., 2005), and that the cross-talk between alveolar epithelial cells 
and leukocytes, which is mediated by ICAM-1 leads to enhanced TNF-α production (Lee et 
al., 2004). ICAM-1 transcription is regulated by several transcriptions factors including NF-κB 
and AP-1. Due to the fact that we demonstrated an inhibitory effect of ANP on these 
transcription factors, we investigated whether ANP administration possibly leads to a 
reduced ICAM-1 expression on alveolar epithelial cells. TNF-α increases ICAM-1 surface 
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expression dependent on dosage and time of TNF-α administration, but interestingly, ANP 
does not alter this expression (figure 16). This is astonishing, because NF-κB is described as 
the predominant transcription factor responsible for ICAM-1 expression in these cells 
(Holden et al., 2004). In contrast, ANP has shown its ability to decrease TNF-α induced 
ICAM-1 expression in HUVECs in previous experiments done in our laboratory (Kiemer et 
al., 2002e). The promoter of ICAM-1 contains various transcription factor binding sites 
besides NF-κB, including AP-1, AP-2, Ets-1 and Sp-1 (Roebuck and Finnegan, 1999). 
Although ANP has an inhibitory effect on DNA binding activity of NF-κB and AP-1, this 
reduction does not seem to be sufficient enough to influence ICAM-1 surface expression in 
the alveolar epithelium.   
Discussion 
85 
5.2 Effects of ANP during LPS-induced septic shock in 
the murine lung 
 
In this part of the work we investigated the in vivo relevance of our previous findings and 
examined potential protective effects of ANP on inflammatory processes in the lung. 
On this account, we used a mouse model of LPS-induced septic shock and investigated 
several important mediators in endotoxin-induced lung injury. 
 
5.2.1 ANP preconditioning reduces LPS-induced NF-κB activation 
 
The transcription factor NF-κB is a central participant in coordinating the transcription of 
many important immunregulatory mediators involved in sepsis, such as TNF-α, IL-8, ICAM-1 
or cyclooxygenase-2 (COX-2). Many genes regulated by NF-κB in response to infection can 
induce further activation of this transcription factor. This can lead to potentiation of 
inflammatory responses in the host and to subsequent organ dysfunction and death 
(Abraham, 2003).  
In this work we demonstrate that ANP is able to protect the lung against LPS-induced NF-κB 
activation (figure 17). The inhibitory effect of ANP on NF-κB activation has been shown 
previously in LPS or IFN-γ treated macrophages (Tsukagoshi et al., 2001; Kiemer et al., 
2000a), in TNF-α stimulated or hypoxia treated endothelial cells (Irwin et al., 2005) and in 
ischemia reperfusion injury in the rat liver (Kiemer et al., 2000b). We were able to 
demonstrate a reduced NF-κB activity in TNF-α stimulated lung epithelial cells in this work 
as well. These findings indicate that inhibition of NF-κB by ANP occurs in a variety of 
different cell types and tissues. In addition, NPR-A deficient mice have been reported to 
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show increased NF-κB activation in hypertrophic hearts, which is caused by an impaired 
cGMP signalling, therefore supporting our results (Vellaichamy et al., 2005). 
Pulmonary activation of NF-κB is described to play a pivotal role in various acute and chronic 
lung disorders, like asthma, COPD (chronic obstructive pulmonary disease) and endotoxin-
induced lung injury. Several studies exist concerning the effects of ANP on the genesis of 
asthma in humans (Hulks et al., 1989; Fluge et al., 1995; Chanez et al., 1990; Almirall and 
Hedenstierna, 1991). On the one hand ANP seems to promote allergic inflammation by 
acting on both immune and non-immune cells, but on the other hand, airway hyperreactivity 
is reduced by intravenous or inhalative administration of ANP (Mohapatra et al., 2004). 
Recent reports revealed protective effects in endotoxin-induced lung injury through 
administration of NF-κB decoys (Matsuda et al., 2005). On account of this, inhibition of  
NF-κB activity seems to be an important step in protecting lungs from LPS-induced injury. 
 
5.2.1.1 Effects of ANP on phosphorylation and degradation of IκBα 
 
Activation of NF-κB is regulated by its inhibitory protein IκB, which masks the nuclear 
localisation sequence of the p65 subunit and retains the p65/p50/IκBα complex in the 
cytoplasm, thereby inhibiting its function as transcription factor. IκB exists in several 
isoforms, IκB-α/β/ε and IκBγ, from which IκBα is the best characterised. Hence, the 
phosphorylation, ubiquitylation and subsequent degradation by 26S proteasome of IκBα is a 
crucial step in NF-κB activation (Karin and Ben Neriah, 2000). Most of the previous studies 
investigating effects of ANP on NF-κB didn’t examine the influence of ANP on 
phosphorylation and degradation of IκB-α in response to pro-inflammatory stimuli. (Irwin et 
al., 2005; Kiemer et al., 2000b; Tsukagoshi et al., 2001) In HUVECs, ANP did not influence 
TNF-α induced degradation of IκB-α, whereas it delayed the degradation of IκBε (Kiemer et 
al., 2002e). Interestingly, the results of the present work indicate that ANP affects the 
degradation of IκBα in response to LPS (figure 19). These findings were accompanied by the 
Discussion 
87 
observation, that in addition the phosphorylation of IκBα, which is essential for subsequent 
ubiquitylation and degradation, is delayed in lungs of ANP treated mice (figure 18). On 
account of this, ANP is suggested to affect signalling pathways upstream of IκBα, to inhibit 
and therefore to lead to a weakened NF-κB activation in response to inflammatory stimuli. 
This work is the first report which leads to the assumption that ANP inhibits IκBα 
phosphorylation and may interfere with inflammatory signals leading to IκBα 
phosphorylation. Further studies are now required to investigate which pathways upstream 
of IκB-α are modulated by ANP. 
In addition, we observed an increase in total IκBα protein levels in ANP treated mice 30 min 
after ANP administration. Elevated protein levels of IκB-α might contribute to a decreased 
NF-κB activation in response to LPS by inhibiting the translocation of its subunits into the 
cytoplasma. The ability of ANP to elevate the expression of IκBα protein has been described 
previously by our research group in endothelial cells (Kiemer et al., 2002e). These data 
support our findings. ANP causes transcriptional up-regulation of both IκBα and IκBε protein 
in HUVECs. A possible influence of ANP on IκBε protein levels in endotoxin-induced lung 
injury was not investigated in this work. Limitation of NF-κB signalling via up-regulation of 
IκBα protein levels has also been described for other substances, including glucorticoids 
(Costas et al., 2000) and TGF-β (Azuma et al., 1999). In addition, up-regulation of IκB by 
NF-κB itself is known as part of a central feedback loop pathway controlling NF-κB 
activation. In our model of LPS-induced lung injury it is likely, that up regulation of IκBα by 
ANP contributes to the weakened NF-κB activation, but considering the minor 
phosphorylation of IκBα in response to LPS, ANP seems to modulate also upstream targets 
of IκBa leading to the phosphorylation and thereby influences this pathway at least through 
two different mechanisms. 
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figure 33 Influence of ANP on NF-κB activation in the lung 
 
5.2.2 ANP inhibits AP-1 binding activity in septic mice 
 
Activation of the transcription factor AP-1 occurs in response to a number of diverse stimuli 
including oxidative stress, DNA damage or exposure to pro-inflammatory cytokines (Shaulian 
and Karin, 2002). Besides its well known functions in cell proliferation, differentiation, 
transformation and apoptosis, growing evidence occurs that AP-1 also has crucial functions 
in the inflammatory response of the lung (Guo et al., 2002; Bozinovski et al., 2002). The role 
of AP-1 in TLR mediated and cytokine induced signalling was investigated in an extensive 
way in vitro (Yuksel et al., 2002; Guha and Mackman, 2002; Gertzberg et al., 2000; 
Janssens et al., 2003), but data concerning AP-1 activation during acute lung injury in vivo 
are rare. Recently it has been demonstrated that activation of AP-1 occurs in a model of  
IgG immunocomplex-induced acute lung injury (Guo et al., 2002). Bozinovski et al. described 
an AP-1 activation after transnasally instillation of LPS (Bozinovski et al., 2002). On account 
of this, and due to the fact, that ANP has shown to attenuate TNF-α induced AP-1 activity in 
alveolar epithelial cells, we investigated the effects of ANP on AP-1 in the lung during 
endotoxaemia. In the present work an increased AP-1 activation is demonstrated 30 min 
after LPS administration and ANP was able to completely prevent this event (figure 20). As 
pointed out in 5.1.3, ANP showed varying results regarding inhibitory actions on AP-1 in 
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previous studies. Activation of this transcription factor can be regulated by two distinct 
mechanisms, the transcription of jun and fos genes and the activation of these subunits via 
phosphorylation by MAPK. Up to now, it is still not clear which of these pathways involved in 
AP-1 activation is affected by ANP. In recent studies, ANP has been shown to inhibit 
endothelin-1 induced activation of AP-1 in glomerular mesangial cells via inhibition of ERK 
and JNK, but did not have any effect on IL-1β induced AP-1 activation (Isono et al., 1998). 
Inhibition of JNK activity by ANP  in response to VEGF stimulation has also been shown in 
bovine aortic endothelial cells (Pedram et al., 2002). Activation of ERK is described to be a 
critical event in LPS-induced AP-1 activation in the lung (Bozinovski et al., 2002) via 
phosphorylation and stabilizing of c-Jun and thereby enhancing  the trans-activation and 
DNA binding of AP-1 (Shaulian and Karin, 2001).  
Our investigations concerning possible effects of ANP on this MAPK revealed very 
heterogeneous results, because activation of ERK differed enormously even within the NaCl 
treated group and no explicit difference between control and LPS-treated mice could be 
observed (data not shown). On this account, we are not able to specify the pathways leading 
to the reduction of LPS-induced AP-1 activation.  
Previous studies in our research group done by Dr. Nicole Bildner revealed that ANP alone 
is able to induce AP-1 activity in HUVECs. This induction is mediated by a heightened 
activation of JNK and ERK. In other systems including LPS-treated murine macrophages 
(Kiemer et al., 2000a) or ischemia reperfusion injury in the rat liver (Kiemer et al., 2000b), 
ANP had no effect on basal AP-1 activation. The data presented in this work do not reveal 
an influence of ANP on basal AP-1 activity in the lung. 
 
5.2.3 Influence of ANP on p38 MAPK in LPS-treated lung 
 
The p38 MAPK pathway is very important in the regulation of various stress-induced cellular 
functions and it is critically involved in the signal transduction of LPS leading to expression of 
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pro-inflammatory cytokines such as TNF-α, IL-2 and IL-12 (Dong et al., 2002). Recent 
studies showed, that suppression of p38 MAPK could be a useful therapy for attenuating the 
inflammatory response (Adcock and Caramori, 2004; Kumar et al., 2003). Furthermore, 
activation of p38 MAPK is more and more regarded to play a crucial role in the development 
of acute respiratory distress syndrome (Obata et al., 2000). 
 
5.2.3.1 p38 MAPK is activated in LPS-induced lung inflammation 
 
The p38 MAPK contributes to the development of ARDS by influencing several cell types. 
On the one hand p38 MAPK suppresses the cytokine production in alveolar macrophages; 
on the other hand p38 MAPK is required for binding of neutrophils to vascular endothelium 
being a major step in the extensive pulmonary neutrophil sequestration seen in the course of 
ARDS (Schnyder-Candrian et al., 2005). Interestingly, controversial reports exist concerning 
p38 MAPK activation during lung injury in vivo. In models of complement-induced lung injury 
(Nash and Heuertz, 2005) and in studies working with cecal ligation and puncture (CLP) 
(Singleton et al., 2005), p38 MAPK activation could be observed in lung tissue during the 
onset of lung inflammation. However, two studies using intranasally instilled LPS obtained 
contradictory results. Schnyder-Candrien and co-workers observed a rapid increase of p38 
activation in LPS-treated mice detected by in vitro phosphorylation assay (Schnyder-
Candrian et al., 2005), while Bozinovski did not observe increased p38 MAPK activation in 
mice detected by Western Blot (Bozinovski et al., 2002). The results presented in this work 
show a marked increase in p38 MAPK phosphorylation investigated by immunoblotting in the 
lung after intraperitonial LPS administration (figure 21). 
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5.2.3.2 ANP decreases LPS-induced p38 MAPK activation in the lung 
 
Being a prominent target for anti-inflammatory therapy and having an important function in 
LPS-mediated AP-1 and NF-κB activation and subsequent cytokine production, we focused 
on potential effects of ANP on p38 MAPK activation next. The results of the present work 
provide evidence, that ANP pretreatment is able to lessen p38 MAPK activation in the lung 
occurring in the onset of endotoxic shock (figure 22). ANP was described previously to 
influence p38 MAPK activation in vitro by our laboratory and by other research groups. 
TNF-α production was reduced by ANP treatment in IFN-γ activated macrophages via an 
attenuation of p38 MAPK activation (Tsukagoshi et al., 2001). Moreover, we were able to 
describe that ANP exerts protective effects on TNF-α induced endothelial permeability by 
inhibition of p38 MAPK activation (Kiemer et al., 2002d). ANP was shown to cause this p38 
MAPK inhibition by induction of MAPK phosphatase-1 (MKP-1) via Rac1 and NAD(P)H 
oxidase (Nox2) activation (Furst et al., 2005). In addition, Irwin and co-workers described an 
inhibitory effect of ANP on hypoxia and TNF-α induced p38 MAPK activation in pulmonary 
endothelial cells (Irwin et al., 2005). These papers support our finding of ANP inhibiting p38 
MAPK and examining possible effects of ANP treatment on MKP-1 would be an interesting 
target for further investigations. Up to now, all studies investigating inhibitory effects of ANP 
on p38 MAPK phosphorylation have been done in vitro. This work shows for the first time an 
inhibitory effect of ANP on p38 MAPK activation in inflammatory conditions in vivo.  
Targeting p38 MAPK for anti-inflammatory treatment is an attractive approach and many 
studies have already been made in which low molecular p38 MAPK inhibitors were 
investigated in various inflammatory diseases (Kumar et al., 2003). In the literature, a 
protective effect of p38 inhibition in acute lung injury is described. For example,  
compound 37, which is a specific p38α,β MAPK inhibitor, was able to prevent  
LPS-induced bronchoconstriction and neutrophil recruitment into the lungs and 
bronchoalveolar space in mice (Schnyder-Candrian et al., 2005). Neutrophil influx and 
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protein leak was also inhibited by oral administration of the p38 MAPK inhibitor SB203580 in 
a murine model of complement-induced acute lung injury (Nash and Heuertz, 2005). Even 
though older reports proposed no central role for p38 MAPK in acute lung injury (Arcaroli et 
al., 2001) and actually reported reduced bacterial clearance and increased cytokine 
production in the lungs of p38 MAPK-inhibited mice (van den et al., 2001), newer data clearly 
indicate a protective role of p38 MAPK inhibition in inflammatory processes in the lung. On 
account of this, we propose a protective role of ANP-mediated p38 MAPK inhibition in the 
lung of LPS treated mice. As discussed in 5.2.5 and 5.2.6, we aimed to clarify potential 
effects of this reduction on hallmarks of acute lung inflammation in later steps in our 
investigations.  
 
5.2.3.3 ANP leads to enhanced p38 MAPK activation in lung tissue 
 
Investigation of p38 MAPK in our model of LPS-induced lung injury revealed astonishing 
results regarding activation of p38 MAPK in ANP treated mice. Surprisingly, we were able to 
detect an increase of phosphorylated p38 MAPK in lungs of ANP-treated mice (figure 23), 
even though a decrease of LPS- induced p38 MAPK activation was observed in ANP 
preconditioned mice as discussed in 5.2.3.2. Up to now, the only report recording an 
activation of basal p38 MAPK activation by ANP comes from our laboratory and was  
p38
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figure 34 Dual effect of ANP on p38 MAPK activation 
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performed in a model of ischemia reperfusion injury (Kiemer et al., 2002b). In addition, data 
concerning an effect of the second messenger cGMP generated by NPR-A and NPR-B on 
this MAPK is rare. An influence of cGMP on p38 MAPK was described in isolated mouse 
platelets, where cGMP induced PKG activation caused p38 MAPK activation (Li et al., 2006). 
Similar observations were made in isolated cardiac myocytes, where sodium nitroprussid 
leads to cGMP generation and subsequent p38 MAPK activation (Kim et al., 2000). In order 
to confirm the data obtained by immunoblotting we investigated p38 MAPK activity by an in 
vitro phosphorylation assay and corroborated ANP-mediated increase in activity. This is the 
first report that ANP is able to increase p38 MAPK activity in the lung. Cellular responses 
following p38 activation are multifarious and highly stimulus and cell-type dependent. For 
instance, p38 MAPK is known to stimulate AP-1 activity through phosphorylation of the 
transcription factors ATF-2, Elk-1 and CCAAT enhancer binding proteins (C/EBPs), which 
then bind to the promoter elements of jun and fos and regulate their transcription (Reddy and 
Mossman, 2002). In our study, AP-1 is not activated in response to ANP alone, indicating 
other effects of p38 MAPK in response to ANP. Furthermore, many studies have been 
published concerning the relationship between p38 MAPK and NF-κB activation. In brief, 
contradictory data exist referring to this topic. On the one hand p38 MAPK has been 
implicated in contributing to NF-κB activity in response to inflammatory stimuli (Craig et al., 
2000; Carter et al., 1999a), on the other hand several reports exist, that rapid p38 MAPK 
activation can have inhibitory effects on NF-κB activation, even though they can cause p38 
MAPK activation themselves (Alpert et al., 1999; Bowie and O'Neill, 2000). In account of this, 
we suppose that rapid ANP-mediated activation of p38 MAPK might contribute to its 
inhibitory effect on NF-κB activation. 
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5.2.4 Influence of ANP on Akt kinase in LPS-treated lung 
 
The protein kinase Akt is involved in various cellular responses including survival, 
proliferation and gene expression (Song et al., 2005; Neri et al., 2002). In the last years, 
evidence increased that Akt also participates in the regulation of cellular inflammatory 
responses. Since several reports have been published proposing an influence of ANP on 
PI3K/Akt pathway, we focused in the following on this protein kinase. 
 
5.2.4.1 Activation of Akt in LPS-induced lung inflammation 
 
In our model of endotoxaemia, we observed increasing Akt activation (figure 25). This event 
has been demonstrated to contribute to pulmonary neutrophil accumulation and the 
development of acute respiratory failure in preclinical models of sepsis (Yum et al., 2001). 
On account of this, we were now interested whether ANP has any effect on LPS-induced Akt 
activation in the lung. 
 
5.2.4.2 ANP reduces LPS-induced Akt activation in the lung 
 
In our model of LPS-induced septic shock, ANP treatment was able to decrease Akt 
activation occurring in the lung after LPS administration (figure 26). Up to now, several 
studies have been made investigating potential influence of ANP on Akt signalling in the 
promotion of anti-apoptotic effects. For instance, Kato and co-workers reported recently, that 
ANP is able to promote cardiomyocyte survival by cGMP-dependent nuclear accumulation of 
zyxin and Akt (Kato et al., 2005). In addition, recent results of our laboratory indicate, that 
ANP treatment mediates anti-apoptotic effects in hepatic ischemia reperfusion injury via the 
Discussion 
95 
PI3K/Akt pathway (Grutzner et al., in press). To our knowledge, no data exist investigating a 
potential influence of ANP on Akt pathways activated in inflammatory response.  
Data concerning the role of Akt activation during inflammatory processes and their impact on 
severity and outcome of injury are very controversial. Guha and co-workers showed that the 
PI3K pathway negatively regulated LPS induction of TNF-α and tissue factor expression. 
Inhibition of PI3K was described to increase LPS induced activation of MAPK pathways,  
AP-1 dependent transcription of NF-κB in mouse macrophages (Guha and Mackman, 2002). 
Inhibition of PI3K by using the inhibitor Wortmannin strongly enhanced LPS-induced cytokine 
expression and reduced the survival time dramatically in a model of LPS-induced septic 
shock (Williams et al., 2004). Taken together, recent data suggest that the PI3K/Akt pathway 
may be a feedback mechanism that prevents excessive innate immune response as 
proposed by Fukao and co-workers (Fukao and Koyasu, 2003). In contrast, PI3K/Akt 
pathway was reported to be required for LPS activation of NF-κB in macrophages and 
endothelial cells (Ojaniemi et al., 2003; Li et al., 2003). Furthermore, Akt can stimulate the 
transactivation potential of the RelA/p65 subunit of NF-κB via utilization of IKK and activation 
of p38 MAPK (Madrid et al., 2001). Therefore, a decreased Akt activation in ANP 
preconditioned lungs during endotoxaemia might contribute to the other effects on 
inflammatory signalling including observed in our studies, including decreased p38MAPK 
activation and impaired NF-κB activation. 
In addition, we observed a slight increase in basal Akt activation in ANP treated lungs. Due 
to the fact, that ANP mediated Akt activation has been reported previously (Kook et al., 
2003), which support our findings, we suppose that Akt activation by ANP might influence 
LPS-induced pro-inflammatory signalling in a negative way as described by Guha and co-
workers (Guha and Mackman, 2002). Whether the observed reduction of LPS-induced Akt 
activation by ANP entails positive or negative effects in the lung and which pathways are 
involved in this inhibition, remains to be elucidated. 
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5.2.5 Impact of ANP on expression of ICAM-1 and leukocyte 
infiltration 
 
One of the fundamental mechanisms in the development of ARDS is the recruitment of 
leukocytes, especially neutrophils, into the alveolar space (Yang et al., 2003). Therefore, 
expression of adhesion molecules like ICAM-1 is a crucial step in the development of lung 
inflammation. The expression of ICAM-1 in response to LPS is regulated by several kinase 
pathways and transcription factors including NF-κB, AP-1 and p38 MAPK (Roebuck and 
Finnegan, 1999; Aplin et al., 1998). Due to the fact, that we observed an ANP-mediated 
inhibition of these signalling pathways, we further investigated whether ANP can exert 
influence on pulmonary ICAM-1 expression and subsequent leukocyte infiltration. As 
presented in this work, our experiments reveal a slight initial inhibition of ICAM-1 expression 
in the lung after 30 min which was completely abolished 90 min after LPS administration 
(figure 27).  
In former experiments ANP has shown inhibitory effects on ICAM-1 expression in response 
to pro-inflammatory stimuli (Kiemer et al., 2002e). Studies from our own laboratory clearly 
showed, that ANP pretreatment can inhibit TNF-α induced expression of several adhesion 
molecules including ICAM-1 and E-selectin in HUVECs (Kiemer et al., 2002e). Additionally, 
other reports demonstrate the inhibition of ICAM-1 expression via activation of cGMP in 
endothelial cells (Moon et al., 2005). In contrast, this work provides first evidence that ANP 
treatment is not able to exert influence on TNF-α induced ICAM-1 expression in alveolar 
epithelial cells as discussed in 5.1.4. These data leads us to the suggestion, that the slight 
inhibition of ICAM-1 expression observed after 30 min might be caused by an effect of ANP 
on endothelial cells, but ANP has no effect on the cardinal ICAM-1 expression in the lung 
occurring in response to endotoxaemia. 
In addition, we investigated leukocyte infiltration in the lung of LPS-treated mice, because 
this event is a hallmark of lung inflammation and is causally linked to the expression of 
adhesion molecules (Beck-Schimmer et al., 2004). Seeing that ANP hardly had any effect in 
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ICAM-1 expression, we wanted to check if infiltration of leukocytes is not altered, too. The 
results presented in this work revealed, that both 30 and 90 min might be too early points in 
time for an investigation of leukocyte infiltration (figure 28). On account of this, we are not 
able to make a proposition whether ANP pretreatment may have an influence on leukocyte 
infiltration or not. 
 
5.2.6 TNF-α in LPS induced lung inflammation 
 
The importance of TNF-α in the pathogenesis of septic shock has been well documented 
(Cavaillon et al., 2003; Hanada and Yoshimura, 2002). In response to LPS administration, 
TNF-α is produced rapidly and plasma level peak after 90 min (Taveira da Silva et al., 1993). 
Even though the TNF-α promoter contains also binding sites for other transcription factors 
including AP-1, Egr-1 and NF-AT, the expression of TNF-α seems to be predominantly 
regulated by NF-κB (Yao et al., 1997; Shakhov et al., 1990). Since we have demonstrated 
an inhibitory action of ANP on LPS-induced NF-κB activity in this work, we further 
investigated possible effects of ANP on TNF-α expression in lung and serum of LPS 
challenged mice. 
 
5.2.6.1 ANP treatment alters TNF-α serum levels and protein levels in the lung 
 
TNF-α has been shown to have a major impact on the immune response in endotoxaemia. 
Being one of the first mediators to occur in the bloodstream after LPS challenge, it leads to 
subsequent expression and liberation of other cytokines, chemokines, other mediators such 
as adhesion molecules and even accelerates its own expression (Karima et al., 1999; 
Hopkins, 2003; Descoteaux and Matlashewski, 1990). Previous works of our laboratory 
revealed, that ANP reduces LPS-induced TNF-α expression both on mRNA and protein 
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levels in murine macrophages and minors TNF-α production in whole human blood (Kiemer 
et al., 2000a).  The results presented in this work clearly present, that ANP dose-
dependently reduces TNF-α serum levels in a murine model of septic shock (figure 29). The 
impact of TNF-α expression on the outcome in sepsis varies regarding different species 
(Lorente and Marshall, 2005). TNFR1 deficient mice are resistant to endotoxic shock (Pfeffer 
et al., 1993) and an anti-TNF-α treatment is highly efficient in reducing mortality in LPS-
induced sepsis in this species (Beutler et al., 1985; Tracey et al., 1987). In human studies, 
however, anti-TNF-α strategies did not come up their expectations and were only partially 
effective in patients with sepsis (Reinhart and Karzai, 2001). As Melanie Keller, a co-worker 
in our laboratory demonstrated in her doctoral thesis, ANP pretreatment actually rescues 
mice from LPS-induced septic shock. The role of ANP-mediated inhibition of serum TNF-α 
levels in a murine model of endotoxic shock will be further characterized by Kathrin Ladetzki-
Baehs doctoral thesis. The lung has been also described as a potential source of TNF-α 
production during endotoxaemia. Therefore we were interested if ANP pretreatment has an 
influence on TNF-α protein levels in the lung during endotoxaemia. The results presented in 
this work show, that TNF-α protein levels in lungs of ANP pre-treated mice are mildly 
decreased in a dose-dependent manner (figure 30).  
 
5.2.6.2 TNF-α is predominantly located in alveolar macrophages in  
LPS-induced lung inflammation 
 
Especially alveolar macrophages, but also alveolar epithelial cells, vascular smooth muscle 
cells and endothelial cells have been described to express TNF-α in response to LPS 
(Ermert et al., 2003). For this reason we were interested in the cell type which is responsible 
for TNF-α synthesis in our model of LPS-induced lung inflammation and whether an 
influence of ANP can be observed. 
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As presented in this work, counterstaining of alveolar macrophages and TNF-α revealed, 
that TNF-α can be primarily detected in alveolar macrophages in our model of LPS-induced 
lung inflammation (figure 31). This observation coincides with several reports in the literature 
describing TNF-α production after LPS stimulation(Xing et al., 1993; Ohkawara et al., 1992). 
As already mentioned above, alveolar epithelial cells and endothelial cells have been also 
described as potential sources of TNF-α in the lung (Jimenez et al., 2002; Haddad et al., 
2002; Burvall et al., 2005), but staining revealed no presence of TNF-α in these cell types 90 
min after LPS administration in this work. However, it has to be taken into consideration that 
we were not able to detect soluble TNF-α, because released TNF-α would have been 
washed away during preparation of the slices. Interestingly, no difference could be 
determined in TNF-α staining in alveolar macrophages comparing LPS treated lungs with 
ANP pre-treated LPS lungs. By reason that alveolar macrophages were rare in stained 
slices, a quantification of this observation was not possible with this method. 
 
5.2.6.3 ANP has no effect on TNF-α mRNA expression 
 
On account of this, our next experiments focussed on mRNA expression of TNF-α in the 
lung, in order to elucidate whether the impaired TNF-α protein observed in the lung by ELISA 
(see 5.2.6.1) is down regulated on transcriptional level. The results of the present work 
demonstrate that no significant difference between LPS and ANP+LPS treated mice could 
be detected (figure 32). Taken into consideration, that the transcription of TNF-α is 
predominantly regulated by NF-κB (Shakhov et al., 1990), it is remarkable that the reduced 
NF-κB activity found in ANP pretreated lungs after LPS challenge doesn’t seem to lead to a 
reduced TNF-α synthesis. Activation of p38 MAPK kinase is described to lead to stabilization 
of TNF-α mRNA via activation MAPK activated kinase-2 (MAPKAP-2) and subsequent 
phosphorylation of tristetraprolin, a zinc finger protein important for TNF-α mRNA (Mahtani et 
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al., 2001). Due to the fact that ANP has been shown to impair LPS-induced p38 MAPK 
activation as described in 4.2.3.2 in this work, ANP might influence TNF-α protein expression 
on a posttranslational level by modulating TNF-α mRNA stability. This could possibly lead to 
reduced TNF-α protein levels, although TNF-α mRNA level were not impaired. 
serum
TNF-α
mRNA
TNF- α
TNF- α

LPS
 
figure 35 Effects of ANP on TNF-α 
 
 
5.2.7 Outlook 
 
No other possible downstream-targets of NF-κB signalling in response to LPS have been 
investigated so far. Indeed, various other genes associated with inflammatory processes in 
the lung contain putative NF-κB and AP-1 binding sites within their promoters, including 
inducible nitric oxide synthase (iNOS), COX-2 and several matrix metallo proteinases 
(MMPs), thus highlighting the importance of NF-κB as a key regulator of inflammatory gene  
activation (Christman et al., 1998). On this account, further studies will focuse on the 
investigation of outcome parameters influenced by an impaired NF-κB and AP-1 activation, 
in order to characterize anti-inflammatory actions of ANP in the lung in a more detailed way. 
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6 Summary 
 
The cardiovascular hormone ANP is known to exert anti-inflammatory properties in 
macrophages and endothelial cells. This work provides new insight into the inflammatory 
signalling pathways influenced by the ANP in the lung. For these purposes, the effects of 
ANP on both alveolar epithelial cells and a model of LPS-induced lung inflammation were 
characterized. 
 
In alveolar epithelial cells, ANP was shown to inhibit the activation of two major transcription 
factors, NF-κB and AP-1, in response to TNF-α. Astonishingly, this did not result in a 
reduced expression of the adhesion molecule ICAM-1. 
 
ANP was also capable to diminish the activation of AP-1 and NF-κB in lung tissue in vivo 
using a mouse model of LPS-induced septic shock. The inhibition of NF-κB activation was 
caused by a delayed phosphorylation and subsequent degradation of IκB-α as summarized 
in figure 36. In addition, ANP treatment elevated total protein levels of IκB-α.  
p38 MAPK and Akt are important mediators in LPS-induced signalling. We demonstrated an 
activation of these kinases in lung tissue in response to i.p. LPS challenge. ANP  
treatment was able to lessen this activation. Furthermore, exclusive ANP treatment  
resulted in an increased p38 MAPK activation, which might contribute to the observed  
impact on other pathways.  
ICAM-1 expression was not impaired in whole lung tissue. ANP strongly decreased TNF-α 
serum levels dose-dependently, but had only a slight effect on TNF-α tissue levels. 
Interestingly, TNF-α mRNA expression was not significantly reduced. 
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figure 36 Schematic diagram of the signalling transduction pathways influenced by 
ANP pretreatment in LPS-induced lung inflammation 
 
 
Taken together this work demonstrates that ANP is able to diminish several important 
inflammatory pathways which are involved in the development of acute respiratory distress 
syndrome in LPS-induced sepsis. 
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8.1 Abbreviations 
 
aa   amino acid 
ATP   adenosine-5’-triphosphate 
AECCC  American-European Consensus Conference Committee 
AMV   avian myeloblastosis virus 
ANP   atrial natriuretic peptide 
AP-1   activator protein-1 
APS   ammonium persulfate  
ARDS   acute respiratory distress syndrome 
ATF-2   activating transcription factor-2  
BNP   brain natriuretic peptide 
bp   basepair 
BSA   bovine serum albumin 
°C   degree celsius 
cAMP   cyclic adenosin-5’-monophosphate 
CAM   cellular adhesion molecule  
CAPS   cyclohexylamino-1-propane sulfonic acid 
CD   cluster of differentiation    
cDNA   copy deoxyribonucleic acid 
cGMP   cyclic guanosin-5’-monophosphate 
Ci   Curie (1 Ci=3.7x10-7 Bequerel) 
CLSM   confocal laser scanning microscopy 
CNP   C-type natriuretic peptide 
Co   control 
COPD    chronic obstructive pulmonary disease 
COX   cyclooxygenase   
DMSO   dimethylsulfoxid 
DNP   dendroaspis natriuretic peptide 
dATP   2’-desoxyadenosine-5’-triphosphate 
dCTP   2’-desoxycytosine-5’-triphosphate 
dGTP   2’-desoxyguanosine-5’-triphosphate 
dNTP   dATP, dCTP, dGTP, dTTP 
DD   death domain 
DTT   dithiothreitol 
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dTTP   2’-desoxythymidine-5’-triphosphate 
EDTA   ethylene diamine tetraacetic acid 
EGTA   ethylene-glycol-O,O’-bis-(2-amino-ethyl)-N,N,N,N,-tetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
EMSA   electrophoretic mobility shift assay 
ERK   extracellular-regulated kinase 
FACS   fluorescence activated cell sorting 
FCS   fetal calf serum 
FITC   fluorescine isothiocyanate  
h   hour 
HE   hemotoxyline eosine  
HEPES   N-(2-hydroxyethyl)piperazine-N’-(2-ethane sulfonic acid) 
HPRT   hypoxanthine-guanine phosphoribosyltransferase 
HUVEC  human umbilical vein endothelial cell 
IκB   inhibitor of nuclear factor-κB 
ICAM   intercellular adhesion molecule 
IFN-γ   interferon-γ 
IgG1   immunoglobulin G1 
IL   interleukin 
IKK   IκB kinase 
iNOS   inducible nitric oxide synthase 
i.p.   intraperitonial 
i.v.   intravenous  
IRAK   Interleukin-1 associated kinase 
JNK   c-Jun N-terminal kinase 
kDa   kilo Dalton 
l   liter 
LFA-1   leukocyte function associated antigen-1 
LPS   lipopolysaccharide 
m   milli (10-3) 
M   molar 
µ   micro (10-6) 
MAPK   mitogen-activated protein kinase 
MAPKK  mitogen-activated protein kinase kinase 
MAPKKK  mitogen-activated protein kinase kinase kinase 
MBP   myelin basic protein 
MCP-1   monocyte chemoattractant protein-1 
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MD-2   myeloid differential protein-2 
MHC   major histocompatibility complex 
min   minute 
MKK   MAPK kinase 
MMP   matrix metallo proteinase 
mRNA   messenger RNA 
MyD88   myeloid differentiation primary response gene (88) 
n   nano (10-9) 
NF-κB   nuclear factor κB 
NLS   nuclear localisation sequence 
NO   nitric oxide 
NP   natriuretic peptide 
NPR   natriuretic peptide receptor 
PAA   polyacrylamide 
PAGE   polyacrylamide gel electrophoresis 
PAMP   pathogen associated molecular patterns 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PDK   phosphoinositide-dependent kinase 
PH   pleckstrin homology 
PI3K   phosphatidylinositol 3-kinase 
PKB   protein kinase B 
PKG   protein kinase B 
PMSF   phenylmethylsulfonylfluoride 
RT-PCR  reverse transcription PCR 
RT   room temperature 
PVDF   polyvinylidenfluoride 
RIPA   radio-Immunoprecipitation assay 
RNA   ribonucleic acid 
rRNA   ribosomal RNA 
rpm   rotations per minute 
ROS   reactive oxygen species 
SDS   sodium dodecyl sulfate 
sec   second 
SEM   standard error of mean 
SIRS   systemic inflammatory response syndrome 
STE   sodium chloride, Tris, EDTA buffer 
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T/E   trypsin EDTA buffer 
TAB   TAK1-binding protein 
TAK   transforming-growth-factor-β-activated kinase 
TBE   Tris, borate, EDTA buffer 
TBS-T   phosphate buffered saline with Tween 
TEMED  N,N,N’,N’,-tetramethylethylendiamine 
Tfl   thermus flavus 
TGF-β   transforming-growth-factor-β 
TIM   TRAF-interacting motif 
TLR   Toll-like-receptor 
TNF-α   tumour necrosis factor α 
TNFR   tumour necrosis factor receptor 
TRADD   TNFR1-associated death domain 
TRAF   TNF-receptor associated factor 
TRAM   TRIF-related Adaptor Molecule 
TRIF   TIR(Toll/IL-1 receptor) domain containing adaptor inducing IFN-γ 
Tris   Tris-hydroxymethyl-aminomethan 
U   unit 
V   Volt 
W   Watt 
VEGF   Vascular endothelial growth factor 
VCAM   vascular cell adhesion molecule 
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8.2 Alphabetical order of companies 
 
AGFA    Cologne, Germany 
Amersham   Freiburg, Germany 
Bachem   Heidelberg, Germany 
BC assay reagents Interdim Montulocon, France 
BD Biosciences  Heidelberg, Germany 
Biochrom   Berlin, Germany 
BIOCLOT    Aidenbach, Germany 
Biomers.net   Ulm Germany 
Bio-Rad   Munich, Germany 
BioWhittacker   Rockland USA 
Biozol    Eching, Germany 
Canberra-Packard  Dreieich, Germany 
Carl-Roth GmbH   Karlsruhe, Germany 
Cell signaling/NEB  Frankfurt/Main, Germany 
DakoCytomation  Hamburg, Germany 
Dianova    Hamburg, Germany 
Endogen    Rockford, USA 
Finnzymes    Espoo, Finland  
Fuji    Düsseldorf, Germany 
Heraeus   Hanau, Germany 
Kinematics   Luzern, Switzerland 
Kodak    Rochester, USA 
Millipore    Bedford, USA 
Minerva Biolabs  Berlin, Germany 
Molecular Probes/MoBiTec,  Göttingen, Germany 
MWG Biotech AG  Ebersberg, Germany 
Owl Seperation systems, Portsmouth USA 
PAN Biotech AG  Aidenbach, Germany 
PE Applied Biosystems  Hamburg, Germany 
Perkin-Elmer   Überlingen, Germany 
Promega   Heidelberg, Germany 
Quiagen   Hilden, Germany 
Roche    Mannheim, Germany 
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Santa Cruz    Heidelberg, Germany 
Sanovi-Cefa   Hannover, Germany 
Serotec    Düsseldorf Germany 
Stratagene   La Jolla, USA 
Sigma     Deisenhofen, Germany 
Ssniff     Soest Germany 
TECAN    Crailsheim, Germany 
Tocris    Westwood, Ellisville, USA 
USB    Cleveland, USA 
VWR International   Munich, Germany 
Zeiss     Oberkochen, Germany 
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8.3 Publications 
8.3.1 Poster presentations 
 
E. Koch, K. Ladetzki-Baehs, M. Keller, A.K. Kiemer, A. Wendel, A.M. Vollmar 
„ Preconditioning with atrial natriuretic peptide modulates LPS-induced NF-κB activation in 
vivo “ 
Naunyn-Schmiedeberg’s Arch of Pharmacol 2003, 367 (Supplement1) 
45. Frühjahrstagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie in 
Mainz, 2004 
 
K. Ladetzki-Baehs, M. Keller, E. Koch, S. Zahler, A.K. Kiemer, A. Wendel, A.M. Vollmar 
„Preconditioning with the cardiovascular hormone ANP rescues mice from LPS-induced 
sepsis” 
47. Frühjahrstagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie in 
Mainz, 2006 
 
8.3.2 Oral presentations 
 
E. Koch, M. Keller, A.K. Kiemer, A. Wendel, A.M. Vollmar 
„Präkonditionierung mit ANP reduziert die LPS-induzierte NF-κB Aktivierung in der 
Mäuselunge“,  
Doktorandentagung der Deutschen Pharmazeutischen Gesellschaft,  
Freudenstadt-Lauterbad 2004 
 
8.3.3 Original publications 
 
C. Mueller, F. Duenschede, E. Koch, A.M. Vollmar, A.K. Kiemer 
„ Alpha-lipoic acid preconditioning reduces ischemia-reperfusion injury of the rat liver via the 
PI3-kinase/Akt pathway ” 
Am J Physiol Gastrointest Liver Physiol 2003 Oct; 285(4):G769-78 
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8.4 Curriculum vitae 
 
Persönliche Daten 
 
Name:    Elke Koch 
Geburtstag:   06.12.1976 
Geburtsort:   Nagold 
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